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The studies presented in this thesis were conducted at the epilepsy center
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are interested intherelativeeffectivenessandefficiencyofmedical interventionsto




the fieldofepilepsyandevaluating thecostͲeffectivenessof theketogenicdietand
thevagusnervestimulatorforchildrenandadolescentswithintractableepilepsy.This









and frequencybetweenpatients, aswell as in an individualpatient. Somepatients
havemultiple seizuresperday,othersonly seldom.Theclinicalmanifestationsvary
anddependonwhereinthebrainthedisturbancefirststartsandhowfaritspreads.





Worldwide, about 65 million people are estimated to have epilepsy.4 In the












harm, as well as psychological stress due to their unpredictability.8 Epilepsy can
sometimes result in significantdisability, socialexclusionand stigmatization.People
with epilepsy commonly encounter problems in the following areas: education;
employment; driving; personal development; psychiatric and psychological aspects
andsocialandpersonalrelationships.9,10
TheannualtotalcostofepilepsyinEuropeis€15.5billion.11IntheNetherlands,direct
medicalcostswere€248million in2011,which is0.3%of thehealthcarebudget.12
Themaincostdriverishealthcareprofessionalvisitsandhospitalizations,accounting
for almost half of the total direct medical costs (€122 million). Institutionalized





uncontrolled after taking two ormore different AEDs.13 Despite the availability of
newer AEDs, the rates of intractability do not seem to have decreased and the
likelihoodofcontrollingseizuresaftertwoappropriatelychosenAEDsfail,islow.14







by lipolysis and ɴͲoxidation of fatty acids rather than by the breakdown of
carbohydrates.17VNSisapacemakerͲlikedevicethatisimplantedsubcutaneouslyinto
theupperpartofthechestwithaconnectingwirerunningfromthestimulatortoan
electrode that is attached to the vagus nerve.18 Once the stimulator is activated,




studies the medical, social, ethical and economic implications of development,









i.e. costͲbenefit analysis (CBA), costͲeffectiveness analysis (CEA) and costͲutility
analysis(CUA).20
In CBA, attempts aremade to value the consequences of programs inmonetary
terms, inorder tomake them commensuratewith the costs.Potentially, this is the




argument for these clinical measures is the relative ease of measurement and









trialͲbased economic evaluation from modelͲbased economic evaluation. In trialͲ
based economic evaluations, data on resource use and effectiveness are collected
simultaneously, for example, alongside a randomized trial. The benefits of this
approach are that results reflect actual data from real patients, and the internal
validity of the data can be assessed through controlled clinical conditions. The




quality of life data together in onemodel by using techniques of epidemiology or
decision analysis. Its result can, therefore, be generalized in terms of the larger
populationandlifetimecostsandoutcomescanthenbeestimated.Differentmodels
exist, decisionͲtree and stateͲtransition models being the most commonly used.
DecisionͲtreemodelspresentasequenceofdecisionsandchanceeventsover time.
Each chance event is assigned a probability. Alternative decision strategies are
evaluated by calculating their average consequences. A limitation of decisionͲtree











Thereareno limitstothetypesofmeasuresofeffectthatwecan include inacostͲ
effectivenessratio.ForourresultstoaidindecisionͲmaking,however,itisnecessary
tohaveameasureofeffectivenessI)thatallowsdirectcomparisonoftherapiesacross
a number of domains, II) that allows comparison across therapeutic areas and





A commonmethod formeasuring a person’s health state is through standardized
questionnaires, on which participants can indicate how they score in different
predefined health domains (e.g. “I canwalk” to “I am bedridden”). AwellͲknown
instrumentistheEuroqolͲ5D(EQͲ5D)23,whichmeasureshealthusingfivedimensions,
namely:mobility, selfͲcare,usualactivities,pain/discomfortandanxiety/depression.
Furthermore,alldimensionshave three levelsof functioning,namely:noproblems,
some problems and severe problems. Using such an instrument, a health state
description isdeterminedbyacombinationoftheparticipants’answers.Theunique
combination of domains and levels leads to a certainnumber of health states; for
example,theEQͲ5Dcandistinguish243differenthealthstates.
Thenext step is toassignavalue (utility) to thehealthstate.TheEQͲ5Dhasutility
values readilyavailable ina soͲcalled ‘utilityͲtariff’ forall243health states.24,25The
values of the utilityͲtariff are obtained from the general public through structured
choicesets,basedonthetimetradeͲoff(TTO)method.TheTTOapproachmeasures
thepreferencesof thepublic foracertainhealthstate.Themethod involvesasking
respondentstoconsidertherelativeamountsoftime(lifeyears)theywouldbewilling
tosacrificetoavoidacertainhealthstate (i.e.achroniccondition likeepilepsywith
frequent seizures). Respondents may be indifferent given the choice between a







advocated that the management of a disease like epilepsy should incorporate a
shared decisionͲmaking process between doctor and patient.26,27 Shared decisionͲ
making is a process inwhich clinicians and patientswork together to select test,
treatments,management or support packages, based on clinical evidence and the
patient’sinformedpreferences.Withinepilepsytreatmentanddiagnostics,thereare
many decisionswhich have no single ‘best’ choice. Such a decision is sensitive to





patients’ stated preferences. A DCE is based on random utility theory and closely




ismore costͲeffective than usual care in economic evaluations. For ameaningful
comparison, it is necessary to examine the additional costs that one medical
interventionimposesoveranother,comparedwiththeadditionaleffectsorutilitiesit
delivers. In an incremental costͲeffectiveness ratio (ICER), the additional costs and
effectsofinterventionAcomparedtoBarecombinedinthefollowingformula22:

CostA–CostB = ѐC = C
EffectA–EffectB = ѐE = E

TheICERcanbeillustratedgraphicallyonafourquadrantdiagramknownasthecostͲ
effectiveness plane (see Figure 1.1).32 The southͲeast quadrant represents the
instances where the intervention is more effective and less costly than the
comparators (dominates),with the opposite situation in the northͲwest quadrant,
representing interventions thataremorecostlyand lesseffective thancomparators
(dominated).ThenorthͲeastquadrant represents interventions thataremorecostly


























are below a specified ceiling ratio. In the Netherlands, an informal ceiling ratio
between approximately €20,000 and €80,000 per QALY exists, depending on the
burdenofdisease.33


























both stakeholders aim at evidenceͲbased decisionͲmaking, they use different
methodologiesandoutcomes toachieve this commonaim.The first challenge is to
‘merge’HTAoutcomemeasureswithcommonclinicaloutcomemeasuresinepilepsy.
Usually, clinical studiesmeasure the effect of interventions with common clinical
measures (e.g. seizure frequency and sideͲeffects)34Ͳ38, rather than quality of life
measures or (patient) preferences. Secondly, although sideͲeffects of AEDs are
frequently researched39Ͳ41, their economic impact is still largely unknown.42
Furthermore,fulleconomicevaluationsoftheKDandVNS,anddirectcomparisonsof
both interventionsare lacking in the literaturewhichmakes itdifficult forclinicians
andHTA researchers todetermine themostoptimal treatment. Inaddition,due to









Part I of this thesis investigates some of the methodological challenges of HTA
research inthefieldofepilepsy, inrelationtoeconomicaspectsandpreferences. In







methods used relating to the description and valuation based on preferences of
healthstates.Thedebaterelatestoquestionssuchaswhoshouldvaluehealth,howis
health to be valued, and how should health be described? Furthermore, another
practicalissuerelatedtothisdebateistheestimationofQALYswhenutilitiesarenot




argued that including patient preferences in research is indispensable. Chapter 3
investigateswhetherpreferences fordiagnosticproperties canbemeasuredwitha
discrete choice experiment. Patients were led through a stated preferences
experiment inwhich featuresofdifferentdiagnosticmodalities (e.g.EEGandMEG)
werepresented.
Research question 2:What is the economic burden of sideͲeffects due to AEDs in
epilepsy?
Antiepileptic drugs (AEDs) are the most used therapy for epilepsy; there are
(theoretically) approximately 25 different AEDs available for epilepsy patients.
AlthoughtheAEDsare, inmostpatients,veryeffective inreducingthe frequencyof








Researchquestion3:WhatarecostͲeffectiveoptions in the treatmentof intractable
epilepsy?
Patientswhosuffer from intractableepilepsycontinue tohave seizuresafter taking
two ormore different AEDs.When newly developed AEDs appear on themarket,
patientswith intractableepilepsy canpotentiallybenefit.Despite theavailabilityof















costͲeffectivenessdidnotseem tobe feasibleduring the timeofwriting this thesis.
The costͲeffectiveness results based on the data of 48 children and adolescents,
gatheredduringthefirst4ͲmonthsoftheKOEKͲstudy,aresummarizedinchapter7.
As the ketogenic diet and vagus nerve stimulator are both potentially effective
treatments for patients with intractable epilepsy, we aimed to compare the two
therapies in a longͲterm economicmodel. A direct comparison of, and economic
informationonthesetherapiesislackingintheliterature.ThemodelͲbasedeconomic




and limitationsof the researchperformed in this thesis.Asummaryof the thesis is
providedinchapter10andonecanfindaDutchsummaryofthethesisinchapter11.
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Resultsshow that thebesthealthstate (noseizuresandnosideͲeffects) isestimatedat0.89
andtheworststate(seizurestype5twiceadayplusseveresideͲeffects)at0.22(scale:0Ͳ1).An
increase in seizure frequency, occurrence of sideͲeffects, and seizure severity were all




This study provides a utilityͲfunction for transforming clinically relevant epilepsy outcome
measures intoutilityestimates.WeadviseusingourutilityͲfunction ineconomicevaluations,








Qualityof life(QoL) isavery importantoutcomemeasure,notonlyforpatients,but
alsoasaninputforcostͲutilityanalyses.However,theessentialutilitiesarenotalways
available.Especially incaseofmodelͲbased,costͲutilityanalyses,where researchers
aredependenton thepublished literature,suitableutilities forcertainhealthstates
areoftenhardtofind.
Problems in gathering utility values may occur because clinical trials and clinical




temporary symptom of abnormal excessive neuronal activity in the brain.1 The
outwardeffectcanbeasdramaticasawild, thrashingmovementand falling tothe
ground unconscious, or asmild as a brief loss of awareness.Within the field of
epilepsy, threediseaseͲspecific clinicaloutcomemeasures areoftenused to reflect
patients’health,namely; seizure frequency, seizure severityand sideͲeffectsdue to
antiepilepticdrugs(AEDs).Frequencyandseverityofseizuresinpeoplewithepilepsy
vary fromone individual to another. In somepeople, seizures are very severe and
occur frequently despite treatment with AEDs. In others, seizures are mild, less
frequent and more easily controlled by AEDs. Seizure severity is measured using
standardized questionnaires. One of the most frequently used seizure severity
questionnaires focusingon the clinical eventsof a seizure, is theNationalHospital
SeizureSeverityScale(NHS3),arevisedandsimplifiedversionoftheChalfontscale.2
Inorder tobridge thegapbetweenclinical trials,whichmeasure clinicaloutcomes,
andeconomicevaluations,whichrequireutilityvalues, itwouldbepreferable ifone
couldmake clinically relevant epilepsy outcomemeasures applicable to costͲutility
analysis by deriving utility scores for the epilepsy outcome measures. For this
purpose,acommonlyusedmethodisthetimetradeͲoffmethod(TTO).3Thishasbeen
used before in four other studieswhich elicited utilities for epilepsy health states.
Firstly,MaltoniandMessori (1998) intervieweda small seriesof refractoryepilepsy
patients (N=81) in order to classify the patient according to five health states
(‘lamotriginewithdrawalduetoserioussideͲeffects’, ‘noresponse’,‘partialresponse
ofatleast50%seizurereductionwithpersistentseizures’,‘nearlycompleteresponse
ofat least50%seizure reduction’,and ‘complete responsewith total freedom from
seizures’).Thenpatientswereaskedhowmuchoftheircurrentstateofhealththey
wouldbewillingtogiveup inorder to live theremainingyears inexcellenthealth.4
Secondly, Forbeset al. (2003)executedaTTOexperiment amongepilepsypatients
(N=43)inordertoassesspatients’ownhealthstateandtheirhealthstatewitha50%
reduction in seizures;only sevenpatientsunderstood the exercise.5 Thirdly,Carroll






seizure disorder’)while imagining that itwould be one of their childrenwhowas
experiencingthehealthstateunderconsideration.Lastly,Kangetal.(2014)askedthe
generalpopulation(N=300)alsotoassessthreeepilepsyhealthstates(‘SeizureͲfree’,
‘50% or more seizure reduction’, and ‘less than 50% seizure reduction’).7 These
publishedTTOͲstudieselicitedutilitiesforaverysmallnumberofspecifichealthstates
(i.e. 1Ͳ5); furthermore, in these studies, seizure severity and sideͲeffectswere not
(fully)includedinthehealthstatedescription.
Toovercome thisgap, theobjectiveof this study is twofold: firstofall, tocreatea
reliableutilityͲfunctiontotransferclinicallyrelevantepilepsyoutcomestohealthstate
utilitiesbasedonpreferencesofthegeneralpublicmeasuredwiththeTTOmethod,




Health states were developed based on three clinically important diseaseͲspecific
outcomemeasures(i.e.attributes):seizurefrequency,seizureseverityandtreatmentͲ
related sideͲeffects. These attributes were selected based on expert advice and
commonalityofusewithin theclinicalepilepsysetting.Table2.1presents thethree
attributes and their levels. The attribute “seizure frequency” comprises 6 levels
rangingfromnoseizurestotwoseizuresperday.Thelevelsof“seizureseverity”were
based on the description of seizures used in the valuation study of the National


































































off (TTO) exercise for eachof the epilepsy health states. The TTOwas based on a
processofoutwardtitrationtoselectalengthoftimeinahealthstatewithfullhealth
which they regardedasbeingequivalent to10years inanepilepsyhealth state. In
otherwords;participantswereaskedwhich lifetheythoughtwouldbebetter, lifeA
or lifeB (orarethetwoequivalent)?LifeA: livingfor10yearswithinthepresented
epilepsy health state; life B: living t= years in perfect health. In the case that the
participantpreferslifeAtolifeB,tisincreasedby1point(maximumt=10),untilthe
participantbecomesindifferenttowhetheritislifeAorlifeB.Theotherwayaround,
if a participant prefers life B to life A, t is decreased (minimum t=0), until the















The questionnaire was selfͲadministered using online survey software Qualtrics,
version2013 (Qualtrics,Provo,UT,USA). The firstpartof theonlinequestionnaire
consistedof socioͲeconomicandbackgroundquestions/characteristics:age,gender,
educational levelandexperiencewithepilepsy (e.g. friendor familywithepilepsy).
Furthermore,weaskedpatientswhethertheybelieveinlifeafterdeath,asthismight
influence theirwillingness to tradeͲoff life years in the valuating exercise.8 Lastly,
participantswereasked todescribe theirownQoLusing theEuroQolͲ5Dimensions
(EQͲ5D)9includingaVisualAnalogueScale(VAS).Thesecondpartofthequestionnaire
started with background information about epilepsy and quality of life. Next, the
attributes and levels of epilepsy health states were explained and some example
questionswereshownasawarmͲupexercisefortheTTO.Thethirdandfinalpartof
the questionnaire consisted of the TTO exercises and questions about the time
required by the participants to complete the questionnaire and their experience
regardingthedifficultyoftheTTOexercise.
Studyparticipants
Participants from the general population aged >18 years without epilepsy were
recruitedusingeͲmail,personalcommunicationandsocialmedia.Alinkwasprovided
to participants, which gave access to the online questionnaire. As part of this
communication,weaskedtheparticipantstoforwardour invitationtoparticipate in
thestudytotheirfamilyandfriends (againaged>18,withoutepilepsy).Participants
who did not fully complete the questionnaire were excluded from the analyses.
Participants were told that if they decided to complete the questionnaire, they
therebyconsentedtoparticipate inthestudy. Inaddition, informationwasprovided







Utilities (U)werederivedbydetermining thenumberof life yearsone iswilling to
sacrifice in order to become indifferent with regard to the choice between the




effects of the three attributes (seizure frequency, seizure severity, sideͲeffects) on
utility, thereby also to develop the utilityͲfunction, and to determine the effect of
othercovariatesonthehealthstatevaluationoftherespondents.Westartedwitha
random interceptmodel tocapture interͲindividualdifferencesplusanARMAautoͲ
correlated errors model for the unexplained intraͲindividual response variation
throughout the trials.To find thebestmodel for theattributeeffectson theutility,
several models were compared by likelihood ratio (LR) testing, using maximum
likelihood (ML) estimation, sinceML estimation is required for LR tests ofmodels
differing in their fixed/predictorpart.10However, the finalmodelwas reͲestimated
usingrestrictedmaximumlikelihood(REML)estimationtoobtainunbiasedestimates
ofstandarderrors.10
Subsequently, to determine whether participants’ religious belief, age, gender,
educational level, experience with epilepsy (i.e. a close relative or a friend with
epilepsy)andcurrentQoL(EQͲ5DandVASscore)significantlyimpactedthevaluation
exercise, they were included in the model as covariates. Multicollinearity of the




values derived with the lead time tradeͲoff.11 When participants traded off all
10healthy lifeyearstoavoidacertainhealthstate,theywereofferedthepossibility
ofvaluing thehealthstateasbeingworsethandeath (SWD). In thiscase, thesame
scenario was presented using the lead time tradeͲoff approach in which the














Themean age of the included samplewas 43 years;more than half (59.5%)were
women; most of them had an educational level of at least secondary vocational
education(86.1%)and61.9%hadhadnoexperiencewithepilepsywhatsoever.They

































N.a.: not available. නIncludes 17 respondents aged 18–20. *Includes: general vocational school, preͲ






Westartedwithan initialmodelwitharandom intercepttocapture interͲindividual
differences plus an ARMA model for the unexplained intraͲindividual response
variationovertrials,treatingallthreeattributesascategoricalvariablestoallowany
kind of relationship between independent and dependent variables, using “one
seizure per month”, “no to mild sideͲeffects” and “type I seizure” as reference












significantly better model fit (ʖ2=46.039, df=1, p<0.005). Finally, we included
interactions between all attributes and then reduced themodel by deleting nonͲ
significant interactions. This resulted in amodel with an interaction between the
attributes “seizure frequency” and “seizure severity”,which fitted better than the
model without interaction (ʖ2=65.213, df=16, p<0.005), but at the cost of sixteen
additionalparameters (4*4).Compared to theplottedmeanobservedutilityvalues
(Figure2.2a),theplottedfixedpredictedvaluesofthismodel(Figure2.2b) lookvery
similar. To investigate whether the simplified model without interaction is also
acceptable,although strictly speaking significantlyworse (whichmaybedue to the




thusassuming theireffectstobe linear, thismodelwassignificantlyworse than the
model behind Figure 2.2c (ʖ2=55.87, df=6, p<0.005). In relation to the above, it is





VIF<10). Participants’ gender, religious belief, educational level, experience with








themodel.Thefinalmodel is,therefore,amodelwitharandom intercept, inwhich
“seizure frequency”,“seizure severity”and“seizureͲfree”arecategoricalpredictors,












































Variable  Coefficient SE Sign. Coefficient SE Sign.
Intercept .857 .023 .000 .861 .013 .000
Seizurefrequency      
Onceamonth†      
Onceaweek Ͳ.045 .009 .000 Ͳ.053 .010 .000
Twiceaweek Ͳ.102 .009 .000 Ͳ.110 .010 .000
Onceperday Ͳ.113 .009 .000 Ͳ.130 .010 .000
Twiceperday Ͳ.150 .008 .000 Ͳ.171 .009 .000
ExperienceofsideͲeffects* Ͳ.061 .004 .000 Ͳ.068 .004 .000
Seizureseveritydescription      
Seizuretype1†      
Seizuretype2 Ͳ.060 .009 .000 Ͳ.058 .010 .000
Seizuretype3 Ͳ.208 .009 .000 Ͳ.216 .010 .000
Seizuretype4 Ͳ.273 .009 .000 Ͳ.290 .010 .000
Seizuretype5 Ͳ.361 .008 .000 Ͳ.391 .009 .000
SeizureͲfree** .037 .011 .001 .028 .013 .024
SWD:statesworsethandeath;SE:standarderror;Sign.:significance.*ExperienceofsideͲeffectsiscodedas
0,notomildsideͲeffects;1,minorsideͲeffects;2,severesideͲeffects.**SeizureͲfreeiscodedas0,no;1,yes
Note: Bothmodels contain no interactions or other covariates; the random part consists of a random
interceptplusrandomslopeoftheattribute“experienceofsideͲeffects”(withinterceptͲslopecovariance)










The utilityͲfunction, including example utility calculations for three hypothetical
health states, can be found in Figure 2.3. Furthermore,when looking at the total
rangeof impactofeachattribute (i.e.differencebetween “best” leveland “worst”
level), these results indicate that“seizure type”hasa substantially largermaximum
effect on health state valuation than “seizure frequency” and “experience of sideͲ
effects”, and that the latter two attributes have almost the samemaximum effect
(bearinginmindthecodingofexperienceofsideͲeffects).
Additionalanalyses
Table 2.3 also includes the results from the random effectsmodel illustrating the
influenceofvariablesonhealth statevaluationwhenallowingparticipants tovalue
SWD. The inclusion of SWD results in a slightly higher constant term, and all


























This studyhasprovidedutility values for 78health statesbasedon three clinically









It is important thatutilityvaluesareaccuratelyassessed,because in theabsenceof
accuratevalues,researchersperformingcostͲeffectivenessanalysesareoften forced
toguess theutility values fordisease states,possibly leading toextreme variability
andquestionableresults.ThisstudyprovidesautilityͲfunctiontotransformmultiple
epilepsyhealthstatesintoutilitiesvaluedbyafairlylargesampleofthegeneralDutch






convenience sample, not fully representative of the generalDutch population. The
sampleconsistedofslightlymorewomen,wasrelativelyyoung,quitehighlyeducated,
and their own quality of lifewas somewhat lower than that of the generalDutch
population. Secondly, theTTOexercisewas conducted viaa computerizedoutward
titrationmethod. Although participants could consult the researcher via email or
telephone in caseofquestions/difficulties, therewasno interviewerpresentduring
the computerized exercise. Most participants (88.2%) indicated that they had






Finally,althoughmostparticipants indicated that theyhadunderstood theexercise,
potentialmisunderstandingorfatiguecanleadtobiasedresults.
Large differences are found between studies presenting utility values for epilepsy
healthstates.4Ͳ7Thisisduetodifferencesinhealthstatedescriptions,thesampleused
tovaluehealthstates(e.g.patientsorgeneralpopulation),andtheelicitationmethod
used.13 The latter issue, is for example also present in our study, although not




intervention offers good ‘value for money’, they need to be measured in a
methodologically sound and preferably uniform manner. The recommendation
outlined by the ISPOR RCTͲCEA Task force regarding themeasurement of utilities,
called for the use of generic preferenceͲbased outcome instruments, such as the
EuroQol(EQͲ5D),orfordirectutilityelicitationmethods,suchasthestandardgamble
or time tradeͲoff exercises.14Despite the growing use of generic preferenceͲbased
outcome instrumentssuchastheEQͲ5D,therearemanyclinicalstudies,whichhave
recordedoutcomeinformationonlyintheformofnonͲpreferenceͲbasedinstruments.
Likewise, researchersworking in the field of epilepsy are primarily concernedwith
measuring symptoms, disease progression and diseaseͲspecific QoL and the
instruments to do this are generally referred to by economists as nonͲpreferenceͲ
based measures. On the one hand, using clinically relevant epilepsy outcome
measures to calculate utilities, as is done in this study, may have the merit of
sensitivitytodiseaseͲspecificeffectsof interventions.Ontheotherhand,the lossof
comparabilityofutilitieswillfullyoverrulethisgain.
As longas there isnooverallconsensuson theuseofutilitiesandhow tomeasure
them, itwill remaina realchallenge todealwith this issueproperly.Therefore, the





of both methods, utility values derived from clinical outcome measures are not
comparable with those derived from a generic preferenceͲbased QoL instrument,
even though they appear to lie on the same scale (0 to 1). The development of a
utilityͲfunctionbridging the gapbetween clinically relevantoutcomemeasures and
utilities is valuable for research purposes, although there is concern about the
applicationofourresultsineconomicevaluations.Firstofall,whenhealthstatesina
preferenceelicitation studysolelyconsistofclinicaloutcomemeasures, rather than
general items ofQoL, focusing effectsmay occur.15,16 The context of the valuation
exercise isnamelymore specific,and thereforeanexaggerationofhealthproblems
mayoccur,whichwillbereflectedbylowerutilities.Secondly,andincontrasttothe
previousstatement,anupwardbiasofutilityscoresmayoccur,asthefocusofclinical
measures is solely on the physiological aspects of the disease itself, therefore,
capturing coͲmorbidities and/or psychological aspects of the disease might be
difficult.15,16Thirdly,developingautilityͲfunction fromclinicaloutcomemeasures to
utilities is not a clearͲcut exercise.  Decisionsmademay vary per study andwill,
therefore,hampercomparabilitybetweenstudies.17,18
Toconclude,thisstudyprovidesautilityͲfunctionforepilepsyhealthstatesandgives
insight intotherelative impactofclinicaloutcomes inepilepsyonQoL.Thepossible
increaseinsensitivityofoutcomemeasuresbyusingourutilityͲfunctioncomesatthe
price of a loss of comparability between utilities.We, therefore, advise only using
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Diagnosing epilepsy is a lengthy and burdensome process for patients and their family.
Although the need for a more patientͲcentered approach in clinical practice is widely
acknowledged, empirical evidence regarding patient preferences for diagnosticmodalities in
epilepsy ismissing.Theobjectivesof this studywere1) to identify towhatextent important





A discrete choice experiment was performed to determine patients' preferences, which
involved presentation of pairwise choice tasks regarding hypothetical scenarios. Scenarios
varied along six attributes: “way of measuring brain activity”, “duration”, “freedom of
movement”, “travel time”, “type of additional examination”, and “chance of additional
examination”. Choice tasks were constructed using a statistically efĮcient design, and the




A totalof289questionnaireswere included in theanalysis.McFadden'spseudoR2showeda
modelĮtof0.28,andallattributeswerestatisticallysigniĮcant.Heterogeneity inpreferences
waspresentforallattributes.“Freedomofmovement”and“Chanceofadditionalexamination”




This study suggests that the identiĮed attributes are important in determining patients'
preference for epilepsy diagnostics. It can be concluded thatMEG is not necessarilymore
patientͲfriendlythanaroutineEEGinprimarydiagnosticsand,regardingadditionaldiagnostics,
patients have a strong preference for longͲterm 24Ͳh EEG over EEG after sleep deprivation.
Furthermore, barring substantial heterogeneity within the parameters in mind, our study







Epilepsy is a severebraindiseasewith a large impactonpatients'qualityof life1,2,
theirfamilyandsurroundings,andsocietyasawhole.3,4Itisoneofthemostprevalent
noncommunicable neurologic diseases and estimated to affect almost 70 million
peoplearoundtheworld.5,6 Internationally,the incidenceofepilepsy isestimatedat
50 per 100,000 people, with large differences between highͲincome countries
(45/100,000) and lowͲ and middleͲincome countries (82/100,000).5–7 Diagnosing
epilepsy is a lengthyprocess that canbe aburden for thepatient andhas a large
impact on the health system, whilemisdiagnoses are quite common. Of patients
diagnosedwithepilepsywhothenareevaluatedatepilepsycenters,20%to30%are
foundtohavebeenmisdiagnosed.8–10
According to several European guidelines,11–13 it is recommended that an
electroencephalography(EEG)shouldbeperformedtosupportadiagnosisofepilepsy
inpatients inwhom theclinicalhistorysuggests that thesymptomsare likely tobe
epileptic in origin. Consequently, EEG is the most used diagnostic procedure for
epilepsy.14However, its sensitivityand speciĮcitydependon several factors suchas
age and recording procedures (e.g., activation procedures such as provoked





children or patients with mental illness, since an EEGsd is considered to be too
burdensomeforthesepatients.
Nonetheless, both 24Ͳh EEG and EEGsd have considerable disadvantages. Sleep
deprivationisshowntoelicitseizures,15–18whichissupportedbythefactthatitisstill
oneof the threemost important seizureͲinducing factorsmentionedbypatients in
questionnaires.19–21 The 24Ͳh EEG impairs patients in their daily routine; wires
attached to the portable EEG recorder constrain them from physical exercises and
limittheirfreedomofmovement.
An alternative to these diagnostic procedures ismagnetoencephalography (MEG),
which seems tobeamorepatientͲfriendlyway todetectepileptiformdischarges,22
potentiallywithgreatdiagnosticvalueintheearlystageofthediagnosticprocess.22Ͳ24
Magnetoencephalography is a noninvasive technique that enables recording of
epileptiform discharges over the whole head, with minimal preparations.









in clinicalpractice and evaluation studies iswidely acknowledged25–27 andpatients'
preferenceshavebeen shown to signiĮcantly impact theirwillingness tousehealth
care services,28–30 empirical evidence ismissing regarding patients' preferences for
routine EEG, EEGsd, 24Ͳh EEG, andMEG as diagnostic tools in epilepsy. Using a
discretechoiceexperiment(DCE),thepresentstudyattemptedtodeterminepatients'
preferences fordifferentelementsof thediagnostic trajectoryofepilepsy.TheDCE
involved presentation of a series of pairwise choice tasks regarding hypothetical
scenarios.31,32Discretechoiceexperimentshaveincreasinglybeenusedinhealthcare
asanapproachtoelicitpatients'preferencesformedicationattributesandhavebeen
applied in similar cases (e.g. patients' preferences regarding several screening
tests).33–37
Therefore, theobjectivesof thisstudywere1) to identify towhatextent important
attributes of diagnostic procedures in epilepsy affect patients' preferences for a




A DCE is an attributeͲbased stated preference valuation technique.32 In DCEs,
individualsarepresentedwithaseriesofhypotheticalchoicetasksandareaskedto
express a preference. The technique is based on the premises that health care
interventions canbedescribedby anumberof attributes and thatpreferences for
these interventions are influenced by the variations (i.e., levels) within these
attributes(seeTable3.1).32
Usingtheseattributesand levels,onecanconstructa“scenario”bychoosinga level
for each attribute. Subsequently, respondents are asked to indicate, by pairwise
comparison of alternative scenarios, which would be their preferred option (see
Figure3.1). In thisway, respondents are encouraged tomake a tradeͲoffbetween
attributesandtheircorrespondinglevels.Afterwards,therelativeimportanceofeach
attribute(andcorrespondinglevels)canbeidentiĮedusingaregressionmodel.
In thisstudy,anunlabeledDCE isused (i.e. thealternativesarenamed“MethodA”
and “Method B”, instead of, e.g. EEG and MEG) mainly because the labeled
alternativesthemselvesconveyinformationtorespondents.Thus,inalabeleddesign,
respondentsmayuselabeledalternativestodeduceinformationwhichtheyperceive






Discretechoiceexperimentmethodology iswelldescribed in the literature.31,32This





































Attributeswere identiĮed based on literature review,11,12,14,15,22 expert and patient
interviews (N=7; three neurologists, two patients, and two laboratory technicians),
and observations during clinical practice. Expert and patient interviews were
semistructured togiveparticipants theopportunity toexplain their thoughts rather
thanforcingthemtochoosefromĮxedresponses.Inourcase,becauseoftheimpact
on the random component variability40 and to minimize cognitive burden41, the
numberofattributeswas limitedtosix.Otherattributeswereconsideredtobe less





measuring brain activity, 2) duration of the recording (DURATION), 3) freedom of
movement(FOM),4)traveltime(TT),5)typeofadditionalexamination(TAE),and6)
chanceofadditionalexamination (CAE) (seeTable3.1).Levels for theĮrstattribute
were chosen to represent a routine EEG recording (electro cap), MEG recording
(helmet), and routine EEG recording with a HydroCel Geodesic Sensor Net.42 The




studies regarding the sensitivity of MEG and EEG.14,22,23,43,44 Other levels were
determined based on expert opinion (i.e. travel time and type of additional
examination)andclinicalcharacteristicsofeachrecording (i.e.durationofrecording
and freedomofmovement). Travel timewas taken into account asup tonow the
availabilityofMEGintheNetherlandsislimited.
Designingchoicesetsandquestionnaire
The choice sets are constructed using Ngene (version 1.1.1, http:// www.choiceͲ
metrics.com/). Four attributeswith three levels and two attributeswith two levels






prior distribution of likely parameter values (e.g. the beta coefĮcients in the
regression analysis) for some or all parameters.47 For example, it is reasonable to




scenarios (see Figure 3.1).We did not include an optͲout option representing the
alternative ‘no diagnostic testing’. In this way, respondents were forced tomake
tradeͲoffs between attributes, and it ensured that respondents could not avoid




choice setwas shown. Subsequently, the choice taskswere presented and, lastly,
respondentcharacteristicswerecollected.
TheĮnalversionofthequestionnairecontained15uniquechoicetasks.Toevaluate



















homedwelling.Patients living inspecializedhealthcare institutions (i.e. forpatients
with mental handicaps) were excluded from the study. Because of the limited
application ofMEG in primary diagnostics of epilepsy, we deliberately contacted
patients fromUMCUwhoareexperiencedwithMEG toensure that thesepatients
wererepresentedinthesample.
Onlypatientswhoagreedtobecontacted forparticipation in (clinical)studieswere
approached.An information letterattached to thequestionnairewas sent to these
patients,whichexplainedthatbyreturningthequestionnaire,respondentsconsented
to participate in the study. Approval for this consent procedure and study was
obtainedfromtheethicscommitteeofKempenhaegheandUMCU.
Statisticsanddataanalysis
Discrete choice datawere analyzed using Nlogit version 5 (Econometric Software,
Inc.).Amixedmultinomial logit (MMNL)modelwasusedtodeterminetheeffectof
theattribute levelsonpatients'preferences.Respondentswhocompleted less than
Įvechoicesetswereexcludedfromtheanalysis.
Mixedmultinomial logitwas chosen to allow forpossiblepreferenceheterogeneity
across respondents and to account for the panel nature of the data.38,52 AMMNL
model is constructed regarding the assumption that parameters are randomly
distributedinthepopulation.Heterogeneitywithintheseparameterscanbeassessed
byestimatingthestandarddeviationoftheparameters.46Therefore,MMNLisableto













inwhich thevalueof the regressioncoefĮcients indicate the relative importanceof
the attribute, V represents the observable relative utility, and ɻi represents the
standarddeviationof therandomparameter.Lastly,ɻij+ ɸijcaptures the individualͲ





the Įrst or the second alternative in the choice task).48 To describe categorical
variables,dummycodingwasusedforeaseofinterpretation(baseͲcaselevelscanbe
foundinTable3.1).
We tested interactionsbetween attributes andbetween attributes and respondent
characteristics.AllparametersincludedintheMMNLmodelweretreatedasrandom








the test–retest and to explore the impact of differences in perceived difĮculty.
Additional analyses were performed on age (two groups, split by mean value),
educationallevel(twogroups,splitbymeanvalue),andgenderbymeansofcreating
interaction termswithin the Įnalmodel. These analyseswere done to assess the
potentialimpactofcovariatesandtoexplainsomeheterogeneitywithinthedata.
ResultsoftheMMNLmodelweretranslatedtoclinicalpractice.Asmentionedabove,
levels for each attribute were chosen based on expert opinion and the clinical
characteristics of each recording. Using this information, one can (hypothetically)
compareroutineEEGandMEGbyselectinglevelswhichcloselyresembletheclinical
featuresofeachrecordingandcalculateoverallutilityscoresusingtheutilityfunction









A total of 304 respondents (30.1%) completed the DCE questionnaire. Excluding
respondentswho completedĮve choice tasksor less,a totalof289questionnaires
wereincludedintheanalysis.Meanageoftherespondentswas45.5years.Nearlyall
respondents reported to have experience with epilepsy diagnosis using EEG
techniques;only5.9% reportednot tohaveexperiencewithanyof the techniques.
Other patient characteristics are presented in Table 3.2.No signiĮcant differences




































McFadden's pseudo R2 shows a model Įt of 0.28. All attributes are statistically
signiĮcant, which provides evidence of the theoretical validity of the model and
indicates that the attributes are considered as being important in determining
patients'preferences.28TheregressioncoefĮcientforeachattribute levelrepresents
the mean partͲworth utility of that attribute level in the respondent sample. A

























To determinewhich attribute has the largest impact on patients'preferences, it is
convenient to look at the relative importance weights as they represent the
importanceofeachattribute inpercentages (seeTable3.4).Asshown,“freedomof
movement”hasthelargestimpactonpatients'preference(27%).Respondentshada
signiĮcant preference for scenarios inwhichminormovementswere possible. The
attribute with the second largest impact on patients' preference was “chance of
additionalexamination”(26%), indicatingthatrespondentspreferreda lowerchance
ofadditionalexamination.Furthermore,respondentshadasigniĮcantpreferencefor
shorter recording (16%), shorter travel times (13%),andsigniĮcantlypreferred24Ͳh
EEGoverEEGsd (14%).Asforthewayofmeasuringbrainactivity (4%),respondents
signiĮcantly preferred the sensor net over the helmet but had no signiĮcant
preferencebetweenthesensornetandtheelectrocap.
Furthermore,standarddeviationsof the randomparameterswere signiĮcant forall








Attribute Totalsample(N=289) Males(N=130) Females(N=159)
Wayofmeasuringbrainactivity 4% 9% 2%
Duration 16% 10% 17%
Freedomofmovement 27% 23% 31%
Traveltime 13% 21% 17%
Typeofadditionalexamination 14% 11% 16%




examined.Modelswith interactionsbetweenattributesand covariates (educational
level, age, experience with MEG/EEG (sd/24 h), difĮculty) were tested, but all
covariates turned out to be nonsigniĮcant. However, a signiĮcant difference was
found between males and females. Results of the model for male and female
respondents are presented in Table 3.5. Female respondents had a significantly
strongerpreferenceforrecordings inwhichminormovementswerepossible,ascan
alsobeseenwhenlookingatthedifferenceinrelativeimportanceweights(seeTable
3.4). Stratified analysis based on gender had large implications on the relative
importanceweights.Inmales,“chanceofadditionalexamination”turnsouttobethe
most importantattribute (26%),whereas in females“freedomofmovement” isstill





Hence, in general, albeit the difference ismarginal, routine EEG is preferred over








Table3.5 Differences between male and female respondents in their preferences for epilepsy
diagnostics.
Attributes Males(95%CI) Females(95%CI) PValue†
Wayofmeasuringbrainactivity
Helmet Ͳ0.36(Ͳ0.66,Ͳ0.06)** Ͳ0.09(Ͳ0.38,0.20) 0.25
 SD:1.16*** SD:1.30*** 
Electrocap Ͳ0.16(Ͳ0.43,0.11) 0.05(Ͳ0.19,0.29) 0.64
 SD:0.84*** SD:0.74*** 
Duration(perminute) Ͳ0.01(Ͳ0.02,Ͳ0.01)*** Ͳ0.02(Ͳ0.03,Ͳ0.02)*** 0.28
 SD:0.02*** SD:0.01*** 
Freedomofmovement Ͳ1.36(Ͳ1.74,Ͳ0.99)*** Ͳ2.14(Ͳ2.55,Ͳ1.73)*** 0.01**
 SD:1.65*** SD:1.97*** 
Traveltime(perminute) Ͳ0.02(Ͳ0.02,Ͳ0.01)*** Ͳ0.02(Ͳ0.02,Ͳ0.01)*** 0.71
 SD:0.02*** SD:0.02*** 
Typeofadditionalexamination Ͳ0.64(Ͳ0.10,Ͳ0.27)*** Ͳ1.12(Ͳ1.47,Ͳ0.76)*** 0.25
 SD:1.96*** SD:1.91*** 
Chanceofadditionalexamination(per%) Ͳ0.05(Ͳ0.07,Ͳ0.04)*** Ͳ0.04(Ͳ0.06,Ͳ0.03)*** 0.08*
 SD:0.09*** SD:0.07*** 
Loglikelihood Ͳ1029.49 Ͳ1134.19 
PseudoRͲsquared 0.24 0.31 
Numberofobservations 1965 2385 
Numberofindividuals 130 158 












Helmet Ͳ0.22(Ͳ0.47,0.02)* Ͳ0.25(Ͳ0.67,0.18) 0.46
 SD:1.29*** SD:0.93*** 
Electrocap Ͳ0.16(Ͳ0.38,0.04) 0.36(0.04,0.67)** 0.04**
 SD:0.91*** SD:0.04 
Duration(perminute) Ͳ0.02(Ͳ0.02,Ͳ0.02)*** Ͳ0.01(Ͳ0.01,0.00)*** 0.67
 SD:0.02*** SD:0.01*** 
Freedomofmovement Ͳ2.01(Ͳ2.35,Ͳ1.67)*** Ͳ1.07(Ͳ1.44,Ͳ0.7)*** 0.85
 SD:1.92*** SD:0.71*** 
Traveltime(perminute) Ͳ0.02(Ͳ0.02,Ͳ0.01)*** Ͳ0.01(Ͳ0.01,0.0)*** 0.89
 SD:0.02*** SD:0.01*** 
Typeofadditionalexamination Ͳ0.87(Ͳ1.19,Ͳ0.55)*** Ͳ0.18(Ͳ0.45,0.10) 0.12
 SD:2.40*** SD:0.50*** 
Chanceofadditionalexamination(per%) Ͳ0.05(Ͳ0.06,Ͳ0.04)*** Ͳ0.03(Ͳ0.05,Ͳ0.01)*** 0.12
 SD:0.08*** SD:0.05*** 
Loglikelihood Ͳ1824.52 Ͳ335.42 
PseudoRͲsquared 0.30 0.16 
Numberofobservations 3795 540 
Numberofindividuals 248 36 


























Electrocap Ͳ0.017 Ͳ0.16 0.05 Helmet 0.22 Ͳ0.36 Ͳ0.09



































To the best of our knowledge, this is the Įrst study to investigate patients'
preferences forEEG techniques in theprimarydiagnosisofepilepsy.Thisstudywas
designedto identifytowhatextent importantattributesofdiagnosticprocedures in






model.52 Our results indicate that respondents would prefer a test with a short





additional examinations” and “freedom of movement”. The attribute “chance of
additionalexamination”wasexpected tohavea large influenceas it relates to the
sensitivityofa recording,which isoften shown tobeofgreat impact inpreference












could be explained by the fact that sleep deprivation may induce seizures and,
therefore,patientsmighttrytoavoidit.Incurrentpractice,24ͲhEEGisoftenusedin
patientswithmental illnessorchildren.However, thisstudysuggests that24ͲhEEG
couldbeamorepatientͲfriendlyalternativeforotherpatientsaswell.Allparameters
contained substantial heterogeneity, which indicates differences in the relative
importanceoftheattributesbetweenrespondents.Apartoftheheterogeneitycould
beexplainedby the interactionbetweenmalesand females regarding theattribute
“freedom ofmovement” and by the interaction regarding the level “electro cap”
betweenrespondentswhosuccessfullycompletedthetest–retestexerciseandthose
who failed the test–retest exercise. These interactions highlight the fact that
preferences couldbe substantiallydifferentbetween subgroups and evenbetween
individualswithinasubgroup.Forexample,differencesbetweenmalesand females
regarding“freedomofmovement”couldhaveanimpactontheirpreferreddiagnostic
modality. Other factors explaining the heterogeneity in preferences could not be
identifiedfromtheavailabledata.
This study has several limitations. First, as Kempenhaeghe and UMCU are centers
notedforexpertiseinthefieldofepilepsy,oftenthemostcomplexorseverepatients






rates to postal questionnaires are approximately 62%56; however, regarding DCEs,
large variations are reported ranging from 10% to 98%.57,58 Some respondents
reported difficultieswhen filling in the questionnaire (i.e. cognitive burden or too
much attributes to take into account)which could be an explanation for the low
response rate. TheDCEmethod canbe cognitivelydemandingwhich could lead to
biased results by reducing respondents' ability to make a wellͲconsidered choice
between different scenarios, especially because epilepsy is often associated with
cognitive impairments.41,59 However, stratified analyses between respondents who







which is relatively high as MEG is currently only used as presurgical evaluation
instrumentorinscientificresearch.Inaddition,areasonableamountofrespondents
(24.2%)reportedtohavenotbeendiagnosedwithroutineEEG.Hence,giventhat in
2012, according to the Dutch Taskforce for Epilepsy Surgery, approximately
180patientswerereferredforpresurgicalevaluationandthefactthataroutineEEG











finding. Furthermore, regarding additional diagnostics, it can be concluded that
patients have a strong preference for 24Ͳh EEG over EEGsd, which could help
physicians in medical decisionͲmaking. Additionally, bearing the substantial
heterogeneity within the parameters in mind, it is important to take individual
preferencesintoaccountinmedicaldecisionͲmakingtoimproveepilepsydiagnostics.
Webelieve that this study canbe a valuable contribution topatient centered care
withinepilepsydiagnostics.Understandingandincorporatingpatients'preferencesin
the diagnostic trajectory of epilepsy (i.e. preferred type of additional examination)
could improve the lengthyandburdensomeprocesswhich isoftenassociatedwith
the diagnosis of epilepsy.10 In addition, incorporating patients' preferences into











unitpriceofa24ͲhEEGoranEEGsdrecording isabout160Euros (price indexyear
2011).63 While the MEG recording is more expensive at first sight, the costͲ
effectiveness(i.e.,valueformoney)ofthismodalityinepilepsydiagnosticswillhighly




compared to the data of a 24h EEG and EEGsd recording.AlthoughColon et al.22
examinedtheadditionalvalueofMEGcomparedtoEEGsd,futureresearchshouldtry
to identifythe informationalvalueofthevariousdiagnostictests inrelationtotheir
financial implicationsasnostudieshaveyetbeenperformedonroutineEEG,EEGsd,
24Ͳh EEG, andMEG in a headͲtoͲhead comparison. Furthermore, future research
should try to identify sourcesofheterogeneitybetweenpatientswithepilepsy and
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sideͲeffects are common. The negative consequences of sideͲeffects can lead to treatment
ranging from minor care to very expensive hospitalization. This cost analysis has been











family costs (i.e. informal care) (€10,472) and mean other costs (i.e. productivity losses)
(€5,747).ExaminingthedifferentcategoriesofsideͲeffectsseparately,rangingfromthemostto
the leastexpensivecategory,thecostestimateswereasfollows:othersideͲeffects(€13,228),
behavioral sideͲeffects (€9,689), general health sideͲeffects (€7,454), cognitive sideͲeffects
(€7,285) and cosmetic sideͲeffects (€2,845)perpatientper year. Subgroup analyses showed










Antiepileptic drugs (AEDs) are potentially an effective treatment for patientswith
epilepsy. Treatment failure and poor adherence are, however, very common in
patientsexperiencingsideͲeffectsduetoAEDs.Inapproximately25%ofthepatients,
sideͲeffects lead to treatment discontinuation1Ͳ3 and have a substantial negative
impacton thequalityof lifeofpatientswithepilepsy.3,4 Furthermore, thenegative
consequencesofsideͲeffectscanhaveasignificantimpactonthelivesofrelativesand
friendsofthepatient,butalsoonsocietyasawhole.
SideͲeffectsofAEDs that commonlyoccur arememoryproblems, fatigue, tremors,
gastrointestinal complaints, osteoporosis, depression, drowsiness, dizziness,weight
change, nausea etc.5 Common sideͲeffects due to AEDs will lead to medical
interventionsranging fromminorcare toveryexpensivespecialistcareandhospital





Noneof these studies focusedon theeconomicburdenof thecommonlyoccurring
sideͲeffects due to AEDs in their analyses. In order to accurately reflect the total
societaleconomicburdenofepilepsy,costsrelatedtosideͲeffectsshouldbeincluded
intheanalysis.





center Kempenhaeghe, Heeze, the Netherlands, between September 2011 and
November2011,receivedapatient information letterbymail includingan invitation
to complete a questionnaire (N=1386). The letter contained information about the
contentof thequestionnaireand thepurposeof the study.Furthermore, the letter
statedthatparticipationwascompletelyvoluntarilyandthatparticipant’sdatawould
be anonymously analyzed and reported. Participantswere invited to complete the
questionnaire only when they had experienced sideͲeffects during the previous
12months. For young children and patientswith severemental retardation, proxy
measureswere taken.Thequestionnairecouldeitherbecompleteddigitallyvia the






The SIDe effects of AED treatment (SIDAED)14 was used as the basis for the
questionnaire.Theoriginal10sideͲeffectcategoriesoftheSIDAEDwerecompressed
into four categories, in order to focus on the most common sideͲeffects and to
condense thequestionnaire.The categoriesused in this studywere: cognition (e.g.
memoryproblems,moreslowthinking,feelingdrowsyorsleepyetc.),cosmetic(e.g.
weightproblems,skin rash,surplussalivaetc.),behavioral (e.g.depressed, irritated,
pressurizedorexcitableetc.)andgeneralhealth (i.e.generalCNS,vision,headache,




employment,andAEDusage).Then the first subdivisionof thequestionnaire starts
with the question ‘Have you experienced any cognitive sideͲeffects, such as slow
reactionormemoryandconcentrationproblems,duringthe last12months?’ Ifnot,
thequestionsaboutcognitivesideͲeffectscanbeskippedandthepatientcangoonto
the subdivision of the questionnaire about cosmeticͲrelated sideͲeffects. Then the
patientswill answer thequestionwhetherornot theyhave encountered cosmetic
sideͲeffects,suchasskinrash,hairlossorweightgain,duringthelast12months,etc.
IfapatienthasexperiencedcognitivesideͲeffects,heorsheisaskedtodescribetheir
complaints and to fill out all the questions about resource use belonging to this
specificcategory.Allcategoriesof thequestionnairearedealtwith in thisway.The
questionsaboutresourceuseareexactlythesameforallfivecategories.Asthecost
analysis isperformedfromasocietalperspective,this impliesthatthemeasurement
of resources has to be broad, i.e. all costs related to use of resources have to be
included, irrespectiveofwhopays.Asaresult,resourceuse inhealthcare,patients
and family and other sectors due to sideͲeffects aremeasured.Health care usage
includesvisitstothegeneralpractitioner,specialists,psychologists,alternativehealth
care,paramedics (i.e.dietician, speech therapistorphysiotherapist),admission toa
general, academic or psychiatric hospital or to an epilepsy center, care received,
includingdaycare,occupationalcare,socialservices,homecare,prescribedandoverͲ
theͲcounter (OTC) medication for sideͲeffects. Patient and family resource use
includes informal careandoutofpocketexpenses.The sector ‘other resourceuse’
includeslossofproductivityandabsenteeismfromactivitiesofdailylife.
Analyzingcosts
The total costswereestimatedusingabottomͲupapproach,where informationon
eachelementofserviceusedwasmultipliedbyanappropriatestandardizedunitcost
andsummedtoprovideanoveralltotalcost.15Theindexyearforthestudywas2012





prices according to providers were used. In accordance with these guidelines,
medicationcostswerecalculatedbasedondailydefineddosagetakenfromtheDutch
pharmaceutical therapeutic compass combined with the Dutch consumer
reimbursementpriceofmedication.18Whendataonmedicationwasdiverse, lowest
costpricesforthespecificmedicationwereused.








assumed that subjects were 100% productive during the hours of partial work
resumption. Productivity losses were calculated based on the Human Capital
Approach(HCA).Thecumulativenumberofcalendardaysofsickleavewasconverted
into workͲhour equivalents based on the mean number of workͲhours per week
registered by the patients. The costs of production losses were calculated by
multiplying the number of sick leave hours by the estimated reference cost of
productionlossforanemployeeperhourofsickleave.17
Despitetheusualskewnessinthedistributionofcosts,arithmeticmeansaregenerally
considered to be the most appropriate measures for describing cost data.19,20
Therefore, arithmetic means are presented. However, to check for sample
uncertainty, nonͲparametric bootstrapping was used. This method is based on
randomsampling,withreplacementbasedontheparticipants’individualdata.21NonͲ
parametricbootstrappingavoids theneed tomakeassumptionsabout theshapeof
thedistribution,suchasnormality,andinsteadusestheobserveddistributionsofthe
cost data in the study being analyzed. The nonͲparametric bootstrap resample







effects. A separate subgroup analysis was, therefore, performed to check for
differencesbetweenpatientsonmonotherapyandpatientsonpolytherapy.Secondly,
as there might be differences between AED and sideͲeffects over time, another






methods can be used to put a value on productivity losses,we corrected for the
methodological uncertainty by calculating productivity losses on the basis of the
frictioncostmethod(FCM) insteadoftheHCA.TheFCM isbasedontheassumption
that an organization needs a certain time span to replace the absent worker by


































Most of the participants (85%) had experienced some kind of general health sideͲ





appear in 68% of the participants. Cosmetic sideͲeffects occur in 42% of the
participantsand7%reportothersideͲeffects.
Table4.2 lists thereferencepricesperunitand thearithmeticmean totalcostsper
category. Table 4.3 shows the bootstrappedmean total costs of all categories and
their 95% confidence intervals. The arithmeticmean costs are comparable to the
bootstrappedmeancosts.Onthewhole,mostcostsaregeneratedinthepatientand
family sector compared to costs inhealth care andother sectors.Overall, informal
care isthemaincostdriveraccountingfor51%ofthetotalannualcostsperpatient.
Production lossesaccountfor43%oftheothersectorcosts,butonlyfor12%ofthe





sideͲeffects category andbehavioralproblems lead tonumerous admissions to the
epilepsy center. Resource use related to daycare ismostly present in the general





Overall, total costs per patient in the category ‘other sideͲeffects’ are the highest.
Thesearebasedona smallgroup (n=15)ofwhicha fewpatientsexperienced side








patient is three timesmore than for apatientonmonotherapy (€2,679 vs. €9,012















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Secondly, totalmean costswere calculated separately for children and adolescent
patients(aged1Ͳ18)andforadultpatientsolderthan18years.Ofall203participants,
50patientswerebetween1Ͳ18yearsofage.Overall,totalmeancostsperpatientdue
to sideͲeffects seem to be higher in children and adolescents. However, in the
categories cosmetic and general health, sideͲeffect costswere higher in the adult
group.NostatisticallysignificantdifferencesincostswerefoundinthedifferentsideͲ






applied in four patientswho exceeded themaximum length of the friction period
(23weeks).Morespecifically,costsofcognitivesideͲeffectsdecreasedfrom€7,285to
€7,104,ofbehavioralsideͲeffects from€9,689 to€9,266andofgeneralsideͲeffects









other sideͲeffectsgenerated themost (€13,228)and cosmetic sideͲeffects the least
costs (€2,845)perpatientper year.Behavioraleffectsgenerate the secondhighest
costsperpatientperyear (€9,689)closely followedbycostsofgeneralhealthsideͲ
effects (€7,454) and cognitive sideͲeffects (€7,285). Furthermore, several subgroup





For example,Pugliatti et al.22 estimated the costof epilepsy in Europebasedon a
reviewwitheconomicmodelingandalsoconcludedthatcostsoutsideformalhealth








the most dominant category was informal care. The euro value of the burden
associated with informal caremay have been even higher than estimated, as we
assumedaminimumwageforallinformalcareproviders.
It can be stated that the economic burden of common sideͲeffects is considerable
comparedwiththecostsofthediseaseitself.Forexample,estimatesshowtotalcosts
of epilepsy per patient per year of only €4,292 in the Netherlands24, €8,275 in
Sweden25,€13,412inDenmark26,€7,738inGermany.27





adverseeffects.The same study showed thatpatients arewilling topayonly€216
(£174)permonthforadrugthatprovidedseizurefreedombutalsocausedhairloss.28
We have to consider certain limitations of our study. Firstly, only subjective
complaintsand relatedhealthcare resourceuse reportedbypatientswereused. It
hasbeenproven that the frequencyatwhich sideͲeffectsofantiepilepticdrugsare
reported inagivenpopulation isdependentonthemethodofassessment.Reliance
onunstructured interviewsor spontaneous reportingunderestimates theburdenof
toxic effects of antiepileptic drugs, whereas use of screening measures, such as
questionnaires or checklists, can result in overestimation.29 Furthermore, caution
shouldbeexercisedwhenrelyingonpatientͲrecordedcostdata30,recallbiasistobe
expected especially with a long time horizon (12months). However, using a cost
questionnaireenabledustoobtainactualdataonpatientandfamilycosts,including
informal care, which cannot be captured through other sources such as hospital
databasesandpatientrecords.
Secondly,sincewedidnotincludeacontrolgroupinouranalyses,wewerenotable
to comparehealth care costs inpeoplewithepilepsywith thehealth care costsof
thosewithoutepilepsy. Ithas,however,alreadybeenproventhatpatientssuffering
from epilepsy are associatedwithhigher expenditure,bothbecauseofbeingmore
likely tohaveexpenses andbecause the averageexpense ishigher.26,31Yoonet al.
(2009)calculatedthehealthcareexpenditureofpeoplewithepilepsyandcomparedit
to thatofnonͲepileptics. They found that the average excessivedirecthealth care
expenditure due to epilepsywasUSD $4,523. Furthermore, they found that adults
withepilepsyreceivedsignificantlymoreinformalcarethanpeoplewithoutepilepsy.
Jennumetal.(2011)showedthatthedirectnetannualhealthcareandindirectcosts
were€14,575 forpatientsand€1,163 for controls, i.e.a consequentexcess costof
€13,412.





Inconclusion, thisstudy,despite its limitations,demonstrates theeconomicburden
inducedbypatientswithantiepilepticsideͲeffects fromasocietalperspective in the
Netherlands. Assuming that more than 80,000 people have epilepsy in the
Netherlands32andthatthedemonstratedcostscanbeashighas€20,751perpatient
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Intractableepilepsy isassociatedwithsignificantmorbidity, impairedqualityof life,mortality
andsubstantialcosts.Theincreasingnumberoftreatmentoptionsandtheinherenthighcosts
havefosteredthedevelopmentofeconomicevaluations intheareaofrefractoryepilepsy.As




This study aimed to provide an overview and a quality check of published full economic




A systematic review of English articles using PubMed and the Centre for Reviews and
Dissemination Database (2000Ͳ2011). Search terms included costͲeffectiveness, costͲutility,














type of economic appraisal and the study design, (3) the outcomemeasures of costs and






and found that certain items were often poorly described, overlooked, or not taken into








on informalcare (familyand friends)andonhealthcareprofessionals (neurologists,
socialworkers,psychologistsetc.).Complicationsduetointractableepilepsyresultin
frequent hospitalizations and many of these patients will eventually live in an
institution.Whenlookingatdifferentgroupsofepilepsypatients,intractableepilepsy





The increasing number of treatment options and the high costs associated with






and effects of interventions. Economic evaluations provide a solution for this
assessment, as they provide information about the relative efficiency of choosing




Economic evaluations are important at different levels of decisionͲmaking. The
MinistryofHealth canuseeconomic evaluations, for example, todeterminewhich
interventions are eligible for insurance packages. In some countries, economic
assessmentsarenowofsuchhigh importancethatadrugwillnotberefunded ifno
economicevaluationisconducted.Butalsoatthelevelofnationalhealthcareservices
orat the levelof the individualpatient,economicevaluations canhelp indecisionͲ
making.Theprincipleofeconomicevaluation is simple:determine the cost/benefit
ratio and select the intervention for which this ratio is the lowest. Although the
principleseemssimple,performingagoodeconomicevaluationstudyisnosinecure.
As influential decisions depend on the results of economic evaluations, the
methodologicalqualityof the assessment shouldbehigh.Unfortunately this isnot
alwaysthecase.Adecadeago,areviewwaspublishedonthemethodologicalquality
of economic evaluations of anticonvulsants.7 Due to the large heterogeneity of
methodologies, the resultsofdifferenteconomicevaluationswerenotcomparable,
making an assessment of costs and effects between interventions impossible. This










iscostͲeffective.Acheap interventionmay representpoorvalue formoney if ithas
little effect on outcome. The general approach of an economic evaluation is to





There are three types of full economic evaluation, namely: CostͲBenefit Analysis
(CBA),CostͲEffectivenessAnalysis (CEA) and aCostͲUtilityAnalysis (CUA). In aCBA,
attemptsaremadetovaluetheconsequencesofprogrammesinmonetaryterms,so
as to make them commensurate with the costs. Potentially, this is the broadest
programmeforjustifyingthecosts.However,expressingbenefitsinmonetarytermsis
often hampered by measurement problems. In a CEA, the consequences of
programmesaremeasured inthemostappropriatenaturaleffectsofphysicalunits,
such as ‘seizureͲfree days’ or ‘seizureͲfree patients’. Themain argument for these
clinicalmeasures istherelativeeaseofmeasurementand interpretation.Oneofthe
majorlimitationsoftheCEAanditsdiseaseͲspecificoutcomeisthatitdoesnotpermit
comparisons with interventions evaluated in other studies. In a CUA, the
consequencesofprogrammesareadjustedbyhealthstatepreferencescoresorutility
weights;that is,statesofhealthassociatedwiththeoutcomesarevaluedrelativeto




health on a scale where death and full health are assigned values of 0 and 1,
respectively.As there aremanyways of obtaining utilities to calculateQALYs, it is
importanttolookatthemethodsusedorthequestionnairechosen.AdiseaseͲspecific
qualityof lifemeasure, forexample, isspecific toan individualdiseaseorcondition
andincludesdimensionsrelevanttothatdisease(e.g.epilepsyͲspecificQOLmeasure:








modelͲbaseddesign. In trialͲbasedeconomicevaluations,dataon resourceuseand
effectivenessarecollectedsimultaneously,forexample,alongsidearandomizedtrial.
Thebenefitsof thisapproachare that results reflectactualdata from realpatients,
and the internal validity of the data could be assessed through controlled clinical
conditions. The disadvantage of this approach is that it may not be possible to
generalizethetreatmentpathwaysandpatientsamplestothe largerpopulation.To






Each chance event is assigned a probability. Alternative decision strategies are
evaluated by calculating their average consequences. A limitation of decisionͲtree
models isthattheprobabilityofeachchanceevent isstatic. Inchronicdiseases,the
probability of chance events changeswith age, health status, and time. Therefore,










one viewpointmay look significantlybetterwhenother viewpoints are considered.
Analyticalviewpointsmay includeanyorallof the following: the individualpatient,
the specific institution, the targetgroup for specific services, theMinistryofHealth
budget, and the community or societal viewpoint. According to guidelines, an
economicevaluationstudyhastobeperformedfromthesocietalperspective.8Inthis






Health care costs of epilepsy are, for example, costs for AEDs, outpatient visits to
physicians,pharmaceuticals,hospitaladmissions,laboratoryinvestigations,etc.Costs
of patient and family are include transportation expense to access care, cost for









tomorrow and costs tomorrow rather than costs today, time preferencehas to be
built into estimates of both costs and effects to reflect their current values. This




The choice of the time horizon is an important methodological consideration in





Everyeconomicevaluationwill contain somedegreeofuncertainty, imprecision,or
methodological controversy. Sensitivity analyses should, therefore, ideally be
performedonboththeeffectsandthecosts inordertochecktherobustnessofthe
results. Univariate sensitivity analysis involves sequentially testing the impact of
changes in single variables on the study findings. Individual parameters are varied
acrossa range that iseitherbasedonavailableevidenceoraccording toa formally
derived estimate. Multivariate sensitivity analysis involves testing more than one
assumptionatatime.Probabilitydistributionsforeachvariabletobetestedmaybe










A literature search was performed in PubMed and the Centre for Reviews and
Disseminationdatabases(theDatabaseofAbstractsofReviewofEffects(DARE),the
National Health Service Economic Evaluation Database (NHS EED) and the Health
TechnologyAssessments (HTA)Database.Asearch in thesedatabases isgenerallya
reliable and valid strategy for finding economic evaluations.12Ͳ13 The search terms
‘economic evaluation’ or, ‘costͲeffectiveness’ or, ‘costͲutility’ or, ‘costͲbenefit’ and




The review focused on full economic evaluations comparing different treatment
options for patients with refractory epilepsy. We nonetheless excluded studies
devoted to surgical treatment of epilepsy, for it is an option restricted to certain
specificformsofepilepsy. Inadditiontotheotherreviews,onlyarticlespublished in
English during the period January 2000 ͲOctober 2011were considered. Eligibility
assessment was performed independently in a standardized manner by three
reviewers.Disagreementsbetweenreviewerswereresolvedbyconsensus.
Datacollectionprocessandqualitycheck




methodology. The checklistwas systematicallyused as aquality assessmentof the





scored both on the epidemiological as well as on the economical part. Possible
differencesinscoringwerediscusseduntilconsensuswasreached.
This qualitative appraisal was conducted by considering the perspective, type of










within the HTA Database). The flow chart of the literature search is presented in
Figure5.1.
After screening the titles and abstracts on inclusion criteria, 113 articles were
excluded;31becausenotreatmentwasgiven,16werenonͲEnglisharticles,15were
duplicates, ten were reviews, two were animal studies, 37 lacked an economic
evaluation, and two articles because the form of epilepsy under researchwas not
refractory epilepsy. Another five articles were eliminated from the analysis after
reading. Despitewhatwas suggested in the title or abstract, in all five cases, the




















Themost recentstudywas from2010,and theoldeststudywaspublished in2003,
using2001data.Alleconomicevaluationswereperformedforfivedifferentcountries.
Thecountriesoforiginof thearticleswere:UnitedKingdom (eightarticles),Canada
(onearticle), theNetherlands (onearticle),Korea (onearticle)andUnitedStatesof
America(onearticle).
130  citations identified
56  abstracts retrieved
17  articles retrieved
12  articles included
- Excluded after reading; no
full economic evaluation (5)
- No economic evaluation (37)
- No refractory epilepsy (2)










thatwill be examined and thus the conclusions drawn, economic analyses should
explicitlymentiontheperspectiveofthestudy.Onlyeightofthestudiesinoursample
didso(Table5.1).Itis,however,likelythattheexternalsourcefinancingthestudywill
give some indicationof theperspectiveof the study.From thearticles thatdidnot
mention the perspective of the study, most studies received funds from
pharmaceutical companies. Overall, two studies20Ͳ21 were not funded by
pharmaceutical companies at all. The authors of only one article claimed to have
conductedtheirresearchbasedonasocietalperspective,16Theirstudyresultscannot,








CUAwas performed and another two articles that include both types of analyses
(Table 5.1). The outcomemeasures used in the CEAswere number of seizureͲfree










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All studies included (some) healthcare costs. Neither patient and family costs nor
costsinothersectorswereincludedinarticles.Therangeofcostsincludedwithinthe
healthcarecategorydifferedwidelybetweenstudies:fromincludingonlythecostof
AEDs in theprimaryanalysis23 to includingcostsof inpatientvisits,outpatientvisits,
laboratory tests,diagnostics,GP visits,nurse visits, andpsychologist contacts etc.16
(Table5.1).
Asmentionedabove,differentoutcomemeasureswereused in thearticles. In two
articles,consequenceswereexpressedin50%ormoreseizurereduction,21,25inthree
articles ‘seizureͲfree days’was the outcomemeasure19,23,24 and in one article the
outcome measure was ‘seizureͲfree patient’.17 Almost 70% of the articles (also)
includedQALYsasameasurementofconsequences.16,18,20,22Ͳ24,26,27Inonearticle,24the
QOLIEͲ31 was used, which is an epilepsyͲspecific QOL measure; the results are,
therefore, not comparable with the other included articles. Furthermore, it is
importantto lookatwhosepreferencesaretaken intoaccountwhenvaluinghealth
states,aspatientandpopulationvalues candiffer significantly.9Three studies18,20,22
usedtheutilitiesderivedfromtheEuroqolͲ5Dquestionnaire(EQͲ5D)whichhasbeen
valuedbythegeneralpopulationtocalculateQALYs.Others16,26,27usedutilitiesfrom
published literaturewhichwereobtainedbythe time tradeoff (TTO)andvaluedby












the differences in both costs and effects statistically. Of these articles, four used
probabilistic sensitivity analysis,20,27 sometimes in combination with oneͲway
sensitivity analysis.23,26Theother fourarticlesused aoneͲway sensitivity analysis,19
sometimesincombinationwithatwoͲwayanalysis22andatothertimeswithamultiͲ
way analysis,16 or with the bootstrapmethod.25 One article did notmention the
methods used for performing the sensitivity analysis, only that the analysis was





sensitivity analysis was mentioned in the discussion, although the results of this
analysiswerenotfoundbyourteamintablesorthewrittentext.
Mainresultsofthestudies
The studies in this reviewevaluatedawide rangeof interventions (Table5.2).One
study compared three interventions,27 another four,25 another five18 andone study
comparedeightinterventions.20AllcalculatedanICERoranICUR.Insomestudies,the
ICERwasexpressed incostsperseizureͲfreeday.19,23,24Othersexpressedthe ICER in
costs per 50% ormore seizure reduction21,25 or in cost per seizureͲfree patient.17




merelyaddͲonAEDscompared to standard therapy,otheraddͲonAEDsorplacebo.
Twoarticlescompared rufinamideaddͲonwith lamotrigineorwith topiramateaddͲ
on.25,27Benedictcalculatedan ICERforrufinamideaddͲonof£2,151per1% increase





al. calculated an ICER for levetiracetam of C$80.70 per seizure free day gained
comparedwithstandardtherapy.19Lorieretal.calculatedanICERforlevetiracetamof
£5,301perseizureͲfreepatientgainedcomparedwithstandardtherapy.17Suh&Lee
calculated for levetiracetam an ICUR of $11,084 per QALY gained compared with
standardtherapy.18
One article compared lacosamide addͲonwith standard therapy and calculated an




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































calculated an ICUR of £34,417 per QALY gained.20 Furthermore, they compared




line lamotrigine compared with first line addͲon therapy with levetiracetam is
followed by second line lamotrigine.22 Therefore, the mean cost per QALY is a
weightedaverageofdifferenttreatments.
Discussion
The increasing number of treatment options and the associated high costs have
fosteredthedevelopmentofeconomicevaluationsintheareaofintractableepilepsy.
As influentialdecisionsdependontheseevaluations, it isofutmost importancethat
theevaluationsareofhighquality.Theaimofthisreviewwastolookatfulleconomic
evaluationsof intractableepilepsy inordertocheckthequalityandto informthose
dealingwith epilepsy treatment decisionͲmaking at the clinical and policy level. In
total,12fulleconomicevaluationswereincludedinthisreview.
Thefactthatallincludedarticlesdifferedsubstantiallyinmethodologyhamperedthe
attempt to synthesize the information regarding several interventions. The most
commondesign foreconomicevaluations inepilepsystudies ismodellingofpatient
outcomes and costs. Thismeans that different sources are used in order to gain
information,suchasdata fromclinical trials,expertpanels,databasesetcetera.The
advantage is that costsandoutcomes canbeestimatedovera longperiodof time
(often lifetime); the disadvantage is that this estimation holdsmany assumptions.
Strikingly,theadvantageofmodellingisoftennotoptimizedinthestudiesincludedin
thecurrentreview,asthetimehorizonof70%ofthearticleswasonlythreeyearsor
less.Thedesignused less frequentlyby the studies included inour review, is trialͲ
based economic evaluation. The advantage of this design is the headͲtoͲhead

















theperspectiveof theanalysis, (2) thenatureofeconomicappraisaland the study
design,(3)theoutcomemeasuresofcostsandconsequencesandtheassociatedtime
horizon inwhich theseoutcomes canbeexpected, (4) thediscountingof costsand





alsodescribed the assessmentof the economic impactof treatmentof epilepsy as
challenging.30 They describe that the economic assessment is in an early
developmentalstageandthatthereisworktobedoneinthedevelopmentofgeneric
andspecificmeasuresofhealthstatesinepilepsythatareappropriateforgeneraluse
in costͲeffectiveness studies. In that same year, Levy (2002) published a
methodologicalreviewwhichrecommendsthatepileptologistsandhealtheconomists
should collaborate to achieve much more robust results by applying better
methodologicalguidelines.7Amore recentlypublished reviewbyBeghietal. (2008)
describesmethodologicaldrawbackssuchasvirtuallyabsent information,shorttime
horizons, sophisticatedmodelswhichdonot representclinicalpractice,useofdata
from indirectcomparisons,andtherareuseofQOLmeasures.31The latter isahuge




did use QALYs as an outcome measure. Unfortunately, this also leads to adding
anothersourceofheterogeneitybecauseofthemanywaysofobtainingpreferences
asdescribedearlier.Themostrecentlypublishedreviewoneconomicevaluations in
epilepsy treatment concluded that although costͲeffectiveness estimates vary
betweenstudies,addͲontherapyforrefractoryepilepsywithAEDsappearstobecostͲ
effective.32 The costͲeffectiveness of the drugs does, however, depend on the
willingnessͲtoͲpayͲthresholdused.
The inferiorqualityof the studieswasnotunique toepilepsy.Previous research in
other fieldshasalsoshown thatsoundeconomicevaluationgenerally receives little
attentionincurrentevaluationstudies,incontrasttomedicaloutcomeresearch.33,34
Conclusions
To summarize, this review addresses several important comments tobe taken into
accountwhenconductinganeconomicevaluationinthefieldofepilepsy,inorderto












1. Kossoff EH, ZupecͲKania BA, Amark PE, BallabanͲGil KR, Christina Bergqvist AG, Blackford R,
Buchhalter JR, Caraballo RH, Helen Cross J, DahlinMG, Donner EJ, Klepper J, Jehle RS, Kim HD,
Christiana Liu YM,Nation J,NordliDR, Jr., PfeiferHH,Rho JM, StafstromCE, Thiele EA, Turner Z,
WirrellEC,WhelessJW,VeggiottiP,ViningEP.Optimalclinicalmanagementofchildrenreceivingthe
ketogenicdiet: recommendationsof the InternationalKetogenicDiet StudyGroup.Epilepsia2009;
50:304Ͳ17.
2. TettoA,ManzoniP,MillulA,BeghiE,GarattiniL,TartaraA,AvanziniG.ThecostsofepilepsyinItaly:a




4. Kotsopoulos IA, Evers SM, Ament AJ, Kessels FG, de Krom MC, Twellaar M, Metsemakers JF,
KnottnerusAJ.Thecostsofepilepsyinthreedifferentpopulationsofpatientswithepilepsy.Epilepsy
Res2003;54:131Ͳ40.
5. PugliattiM,BeghiE,Forsgren L,EkmanM,SobockiP.Estimating the costofepilepsy inEurope:a
reviewwitheconomicmodeling.Epilepsia2007;48:2224Ͳ33.
6. TaylorRS, Sander JW, TaylorRJ,BakerGA.PredictorsofhealthͲrelatedqualityof life and costs in
adultswithepilepsy:Asystematicreview.Epilepsia2011;52:2168Ͳ80
7. LevyP. Economic evaluationof antiepilepticdrug therapy: amethodologic review. Epilepsia2002;
43:550Ͳ8.
8. Drummond MF, O'Brien BJ, Sculpher MJ. Methods for the Economic Evaluation of Health Care
Programmes.NewYork:OxfordUniversityPress;2005.
9. Brazier J,Ratcliffe J,Salomon JA,TsuchiyaA.MeasuringandValuingHealthBenefits forEconomic
Evaluation.NewYork:OxfordUniversityPress;2007.
10. GlickHA,Doshi JA, Sonnad SS, PolskyD. Economic Evaluation in Clinical Trials.New York:Oxford
UniversityPress;2007.
11. MaynardA.ThedesignoffuturecostͲbenefitstudies.AmHeartJ1990;119:761Ͳ5.










16. MaltoniS,MessoriA.LifetimecostͲutilityanalysisofpatientswith refractoryepilepsy treatedwith






19. Blais L, Sheehy O, StͲHilaire JM, Bernier G, Godfroid P, LeLorier JJ. Economic evaluation of
levetiracetamasanaddͲon therapy inpatientswith refractoryepilepsy.Pharmacoeconomics2005;
23:493Ͳ503.
20. HawkinsN,EpsteinD,DrummondM,WilbyJ,KainthA,ChadwickD,SculpherM.AssessingthecostͲ







22. Spackman DE, Yeates A, Rentz AM, Hutton J. The cost effectiveness of zonisamide as adjunctive
therapyinadultpartialseizureepilepsy.JournalofMedicalEconomics2007;10:455Ͳ73.











29. TarnTYH,SmithMD.PharmacoeconomicGuidelinesAround theWorld. Isporconnections2004;10:
5Ͳ15





































ahigh impacton the individualaswellasonsocietyasawhole. Inaddition to theeconomic
burden,epilepsyimposesasubstantialburdenonthepatientsandtheirsurroundings.Patients
withuncontrolledepilepsydependheavilyon informalcareandonhealthcareprofessionals.
About 30% of patients suffer from drugͲresistant epilepsy. The ketogenic diet can be a
treatmentof lastresort,especiallyforchildren.Thebeneficialeffectoftheketogenicdiethas
beenproven,butinformationislackingaboutitscostͲeffectiveness.Inthecurrentstudywewill




InaRCTwewillcompare theketogenicdietwithusualcare.Embedded in thisRCTwillbea
trialͲbasedandmodelͲbasedeconomicevaluation, looking froma societalperspectiveat the
costͲeffectiveness and costͲutility of the ketogenic diet versus usual care. Fifty children and
adolescents (aged 1Ͳ18) with intractable epilepsy will be screened for eligibility before
randomization intothe interventionortheusualcaregroup.Theprimaryoutcomemeasure is
the proportion of children with a 50% ormore reduction in seizure frequency. Secondary
outcomes include seizure severity, sideͲeffects/complaints, neurocognitive, socioͲemotional
functioning,andqualityoflife.Costsandproductivitylosseswillbeassessedcontinuouslybya





The proposed research project will be the first study to provide data about the costͲ
effectivenessof the ketogenicdiet for children and adolescentswith intractable epilepsy, in







Epilepsy is a brain disorder characterized predominantly by recurrent and
unpredictable interruptions of normal brain function. Seizures are transient
occurrences of signs and/or symptoms due to such abnormal excessive or
synchronousneuronalactivities inthebrain.1Differentpartsofthebraincanbethe
siteofsuchdischarges.Theclinicalmanifestationsofseizureswillthereforevaryand
depend onwhere in the brain the disturbance first starts and how far it spreads.
Transient symptoms can occur, such as loss of awareness or consciousness and
disturbances of movement, sensation, mood or mental function.1 Furthermore,
epilepsyisamajorcostͲintensiveandworldwidehealthproblem.2
In 2000, the aggregate burden due to epilepsy was 0.5% of the total burden of
diseasesintheworld.3InEurope,about3.4millionpeoplesufferfromepilepsy.4The
annualtotalcostsofepilepsy inEuropeare€15.5billion.5 IntheNetherlands,direct
medical costs were €221 million in 2005.6 In addition to the economic burden,
epilepsy imposes a substantial burden on the patients themselves and their
surroundings.
In the Netherlands, the point prevalence of epilepsy in children and adolescents
between 0Ͳ18 years is 4.77 boys, and 4.55 girls per 1,000 persons. The yearly
incidence of epilepsy in the Netherlands for children and adolescents between
0Ͳ18years is 0.58 per 1,000 boys and 0.53 per 1,000 girls.7 Although epilepsy is
treatablewith antiepileptic drugs in themajority of cases, about 30% of patients
suffer from drugͲresistant epilepsy.8 Patients with uncontrolled epilepsy heavily
depend on informal care (family and friends) and on health care professionals
(neurologists, social workers, psychologists etc.). Complications due to intractable
epilepsy result in frequent hospitalizations and many of these patients are
institutionalized.PatientswithdrugͲresistantepilepsycanpotentiallybenefit froma
ketogenicdiet.Theketogenicdiet isahighͲfat, lowcarbohydrate,normocaloricdiet
thatmimics themetabolic state of fasting. During a prolonged fast, body energy
requirementsaremetby lipolysis andßͲoxidationof fatty acids rather thanby the
breakdown of carbohydrates. The ketogenic dietmaintains an anabolic nutritional
stateinametabolicsituationoffasting.Ketonebodiesmayproduceananticonvulsant
effect,presumablydue tochanges incerebralenergymetabolism, incellproperties
decreasing excitability, in neurotransmitter function, in circulating factors acting as
neuromodulators and in the brain’s extracellular milieu.9 The ketogenic diet is
generallyusedforaperiodofupto3years.Seizurecontrolbenefitsaretypicallyseen
within1Ͳ3monthsofstartingthediet.Theinternationalstudygroupreportsthatthe
dietshouldbeutilized forat least31/2monthsbeforedeciding todiscontinue it.10












that relatively few children and their parents can comply with the stringent diet.






is a lack of information about the costͲeffectiveness of the ketogenic diet, and
consequentlyhealthauthoritieshavenotbeenconvincedofitsusefulness.





The design and methods of a randomized controlled trial (RCT) evaluating the
(costͲ)effectivenessofaketogenicdietincomparisonwithusualcareinchildrenand
adolescentswithintractableepilepsyaredescribedinthispaper.Thisstudyhasbeen






to changes in seizure frequency and seizure severity, sideͲeffects/complaints,
neurocognitive,socioͲemotionalfunctioning,andqualityoflife?
EconomicEvaluation







From a social perspective, is the ketogenic diet, in comparison with usual care,
preferableintermsofcosts,effectsandutilities?



































Screening exclusion criteria 
by attending physician

















The patient population consists of children and adolescents with drugͲresistant
epilepsy.Patients are eligible toparticipate if theymeet the following criteria: age
between1 and18 yearsold;havinguncontrolled seizures;noteligible for epilepsy
surgery; no fatty acid oxidation disorders and related diseases; no diabetes and
hyperinsulinism; no prolonged QTͲtime syndrome; no hypercholesterolemia or
hypertriglyceridemia;no severe liver, kidneyorpancreasdiseases;no renal tubular
acidosis; no severe behavioral disorder; no malnutrition; no treatment with
topiramateoracetazolamideandnopositive familyhistoryorother risk factors for
kidneystonesoracidosis.
Recruitment
Potential participants are screened for exclusion criteria by their own attending
pediatrician, neurologist or pediatric neurologist. Children who are eligible to be











the ketogenic diet group and usual care, and assuming that alpha=5% and
power=80%,weneed22children foreachgroup.Takingdropouts intoaccount,we
need50childrenintotal.AdropͲoutisdefinedasachildwhodropsoutofthestudy















Patients assigned to the ketogenic diet group will be hospitalized in the tertiary
epilepsycenterforoneweek.Duringthisweektheketogenicdiet is introducedbya
dietician. The antiepileptic drugs the children and adolescents use at the time of
inclusion in the studywill be continuedwithout changes during the study (except
whenmedically indicated). The initial calorie prescription for the ketogenic diet is
based on an average between the preͲdiet intake and the recommendations for
energy requirements, taking into account current and previousweight and height,
recommended caloric requirementsand levelsofphysicalactivity.Thedieticianwill









a treatment of last resort, the children in the usual care groupwill also receive a
ketogenic diet after a delay of four months. The controls will be treated and




visit the multidisciplinary team (nurse practitioner, dietician, paediatrician and










Patients in the usual care groupwill visit themultidisciplinary team (nurse
practitioner,pediatricianandneurologist)at timepointsT0,T2,andT3and
willhaveaneurocognitiveassessmentatT0andT3.IncaseofdropͲout,avisit

















Several instrumentswillbeused to assess theeffectsof the ketogenicdieton the




A seizure calendar is used to record seizures. Types of seizures are described and
















included in the SIDAED form 10 categories: general CentralNervous System (CNS),
behavior (increased irritability),depressivesymptoms,changes incognitive function,







Measurement T0 T1* T2 T3 FU1* FU2* FU3* FU4*
Demographiccharacteristics x       
Clinicalmeasurement x x x x x x x x
NationalHospitalSeizureseverityscale x x x x x x x x
SideͲeffectsofAntiepilepticDrug x x x x x x x x
CredibilityAndExpectancyQuestionnaire x       
PeabodyPictureVocabularytest x   x    x
BeeryDevelopmentalVisualͲMotorIntegrationtest x   x    x
FEPSYcomputerizedtest x   x    x
KaufmanAssessmentBattery x   x    x
Actigraphy x   x    x
SEVQuestionnaire x   x    x
SDQQuestionnaire x   x    x
POMSQuestionnaire x   x    x
ThePersonalAdjustmentandRoleSkillsScale x   x    x
TheHagueRestrictionsinChildhoodEpilepsyScales x   x    x
EuroQol x   x    x
TAPQOLorTACQOL x   x    x
Blood x  x x x x x x
Urine x  x x x x x x
Ketonbodiesmeasurement x x x x x x x x
ECG x   x x x x x
T0:baseline;T1:admission;T2:6weeksafterbaselineperiod;T3:4monthsafterbaselineperiod;FU1:3





The Peabody Picture Vocabulary test (PPVTͲIIIͲNL:Dutch version) is an individually












The Beery Developmental test of VisualͲMotor Integration (BeeryͲVMI) is awidely







The FEPSY is a neurocognitive computerized test battery consisting of different
subtests.Forthisstudyweusethesimpleauditoryandvisualreactiontimes,inwhich
the stimulus exposure endures until a pushͲbutton (spaceͲbar) response is given.29
Simple reaction tests give information on alertness functions and on the speed at
whichthe informationprocessingsystem isactivated.Wealsousethebinarychoice
reaction task in which a combination of accuracy and speed of responses are
measured.Thistestmeasuresthespeedofcentralinformationprocessing.Finally,we




TheKaufmanAssessmentBattery forChildren II (KͲABC II) isused to investigate the









During theadministrationof thePPVTͲIIIand theKͲABCII test,anactigraphicdevice
(Actiwatch®modelAW4:CambridgeNeurotechnologyLtd.,UnitedKingdom)willbe
usedtoassessmotoractivityasameasureofalertness.Assomeofthechildreninthe












The SEV questionnaire (Sociaal Emotionele Vragenlijst: Social Emotional
Questionnaire) is a DSMͲIV oriented questionnaire which is used to assess four






The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioral screening
questionnaire that provides balanced coverage of children and young people’s
behaviors,emotions,andrelationships.32TheSDQ isapplicabletochildrenbeginning
at the age of 4 and asks about 25 attributes that are divided into five relevant





transient, fluctuating affectivemood states: TensionͲAnxiety, DepressionͲDejection,






developed to measure psychosocial adjustment in children with chronic physical
illness.34 This instrument is a brief parentͲcompleted index of youth psychosocial
adjustment.The instrumentyields six factorͲderivedpsychosocial subscales:namely





TheHARCES isaquestionnaireconsistingof11 itemsused toassess impairments in
daily functioning that are related to epilepsy, e.g. how much influence does the
epilepsy have on your child’s freedom of functioning in the house? Items are




The Credibility and Expectancy Questionnaire (CEQ)37 is a multidimensional selfͲ









Livingwithuncontrolled seizureshasanegative impacton thequalityof lifeof the
childandhis/herparents.Therefore,wewillmeasuregenericqualityof lifeofboth
thechildrenand theirparents.For thispurposewewilluse theEuroQol instrument




anxiety/depression.Eachdimensionhas3 levels:noproblems, someproblems and
severe problems, thus defining 243 (35) possible health states. ‘Unconscious’ and
‘dead’ have been added to these states, resulting in a total of 245 states.






Life) for children aged between 1Ͳ5 years39 and the TACQOL (TNOͲAZL Children’s
Qualityoflife)forchildrenagedbetween6Ͳ16years.40Thereare12dimensionsinthe
TAPQOL:lungs,stomach,skin,sleep,appetite,aggressivebehavior,positiveemotions,
fear,vitality, socialbehavior,motor functioningand communication.Alldimensions
arescoredonascale from0Ͳ100.TheTACQOL iscomprisedof7dimensions:bodily
complaints, independence,motor functioning, cognition, social functioning,positive
andnegativeemotions.Thescoresof the first5dimensionsvary from0Ͳ32and the
scoresofthelasttwodimensionsfrom0Ͳ16.
Economicevaluation
The economic evaluation will be performed from the societal perspective, which
implies thatall relevant costsandeffectswillbe taken intoaccount.Theeconomic
evaluationcomparescostsandeffectsoftheketogenicdietincomparisonwithusual
care. A CostͲEffectiveness Analysis (CEA) and a CostͲUtility Analysis (CUA) will be
performed.Outcomesof interest for theCEAand theCUAwillbe the reductionof
seizuresandimprovementintheQualityAdjustedLifeYears(QALYs)respectively.The
QALY is ameasure of disease burden, includingboth the quality (utilities) and the
quantity of life lived. Total societal costs will be calculated based on the Dutch




intervention costs, health care sector costs, costs for the patient and family, and










costprices from theDutchmanual for cost analysis inhealth care researchwillbe
used.42
Productivitylosses
A retrospective questionnaire and the patient modules of the PROductivity and
DISeaseQuestionnaire(PRODISQ)43willbeusedtomeasureproduction lossesofthe





Both generic quality of life, as well as utilities, will be derived by means of the
EuroQol,asmentionedbefore.Utilityvalueswillbecalculatedforallhealthstatesof






AdjustedLifeYears (QALYs).However, toovercome the tariff’sdifferencesbetween
countries,theDutchtariff isalsousedtocalculateutilities inthesensitivityanalysis.
Lamers,45 calculatedbymeansof theTTOmethodaDutch scoring function for the







Our primary (baseͲcase) analyseswill be performed according to the intentionͲtoͲ
treat principle, including data from all participants regardless of whether they
receivedtheinterventionornot.FortheanalyseswewilluseSPSSstatisticalsoftware.
Respondents forwhom at least 75% of the data permeasurement instrument are
availablewillbeincludedintheanalysis.Missingdataonanitemlevelwillbehandled
usingSPSSmissingvalue regressionanalysis.Completelymissingmeasurementswill
be handled using multiple imputation. BetweenͲgroup differences in proportions
(dichotomousvariables)willbe testedusing theChiͲsquare testandbetweenͲgroup
differences inmeans (continuous variables)willbe testedusing Student’s tͲtest for
independentsamples.Inaddition,amultivariateregressionanalysiswillbeperformed
with the covariates of sex, age, severity of disease, duration of disease etc. The
accuracyofthefindingswillbeexpressedintermsof95%confidenceintervals.
IIa)TrialͲbasedeconomicevaluation
A baseline analysis will be performed to examine the comparability of groups at
baselineforbothcostsandoutcomes.Ifnecessary,methodswillbeappliedtocontrol
for differences in baseline.46 A KolmogorovͲSmirnov test will be performed to
investigatewhetherdataaredistributednormally.Despitetheusualskewnessinthe
distribution of costs, the arithmeticmeans will generally be considered themost
appropriatemeasuresfordescribingcostdata.47,48Therefore,arithmeticmeans(and
standard deviations) will be presented. In case the cost data are skewed, nonͲ
parametric bootstrapping will be used to test for statistical differences in costs
between the interventionandusualcare.Thebootstrap replicationswillbeused to
calculate95%confidenceintervalsaroundthecosts(95%CI),basedonthe2.5thand
97.5th percentiles. If cost data are distributed normally, tͲtests will be used. The





The robustness of the ICER will be checked by nonͲparametric bootstrapping.
Bootstrap simulationswill also be conducted in order to quantify the uncertainty




ceiling ratio. Therefore, the bootstrapped ICERs will also be depicted in a costͲ




costͲeffective using a range of ceiling ratios. In addition, to demonstrate the
robustness of our baseͲcase findings, multiͲway sensitivity analyses will be
performed.49
IIb)ModelͲbasedeconomicevaluation
The timehorizonof theCostUtilityAnalysis (CUA)willbeextrapolated towards the
remaining lifeexpectancyof the studypopulation.TheCUA isofmajor importance
since the impact of a ketogenic diet on seizure reduction, costs, andQoL reaches
beyondthe4Ͳmonthstudyperiodoftheclinicalstudy.AMarkovMonteCarlodecision
analytic model will be developed to calculate lifetime incremental costs and
incrementalQALYsoftreatmentwithaketogenicdiet incomparisonwithtreatment
withantiepilepticdrugsonly.Markovmodelsassumethatapatientisalwaysinoneof
a finitenumberofhealthstates.Alleventsare representedas transitions fromone
statetoanother.AfirstͲorderMonteCarloevaluationofaMarkovmodeldetermines
the prognoses of a large number of individual patients. The time horizon of the
analysisisdividedintocycles.Eachpatientbeginsinaninitialstate.Duringeachcycle,
thepatientmaymakeatransitionfromonestatetoanotheraccordingtothelawsof
chance, as dictated by the transition probabilities. After the first patient has
completed the simulation, another patient begins in the initial state and a new
simulation isperformed.Thisprocess isrepeatedavery largenumberoftimes,and
each simulation generates a quality adjusted survival time and costs.Monte Carlo
analysis,asopposedtoaMarkovcohortmodelwithoutmemory,offersthepossibility
to flag subjects inorder to track theircharacteristicsanddiseasehistories; this isa
very flexible approach tomodelling variabilitywithin a population. Themodelwill
combinetheresultsoftheclinicalstudyanddatafromthemedical literature. Inthe
modelling study we will also perform probabilistic sensitivity analysis to test
parameteruncertaintyandtoconstructcostͲeffectivenessacceptabilitycurves.Future
costs and effects will be discounted according to the Dutch guidelines for cost
calculationsinhealthcare.42
Discussion
Our design is aimed at assessing the effectiveness and costͲeffectiveness of a
ketogenic diet among children and adolescents with intractable epilepsy. It is a
prospectiveRCTcomparingtheketogenicdietwithusualcare.
The ketogenic diet can be a treatment of last resort for patientswith intractable
epilepsy.Thisalternative therapy isusedonly in theminorityofchildrenwhocould
potentiallybenefitfromit.Inordertooptimizetherapyforchildrenwithuncontrolled






Compliance with a ketogenic diet is difficult due to its restrictive nature.
Unfortunately,nonͲcompliance limits the intendedeffectand increases thecosts to
society,resultinginalessfavorablecostͲeffectivenessratio.Inordertoovercomethis
problem, the children and adolescentswith uncontrolled epilepsywho are on the
ketogenicdietwillbemonitoredaccordingtoastrictstandardizedprotocol.Therefore
it is likely that the efficiency of patient care will improve. However, a formal
assessment of the diet’s costͲeffectiveness has not yet been performed and is the
focusofthepresentproposal.
Conclusion











1. FisherRS,vanEmdeBoasW,BlumeW,ElgerC,GentonP, LeeP,Engel J Jr.Epileptic seizuresand
epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the
InternationalBureauforEpilepsy(IBE).Epilepsia.2005;46:470Ͳ2.









7. Hoeymans N, Melse JM, Schoenmaker CG: Gezondheid en determinanten. Deelrapport van de
Volksgezondheid ToekomstVerkenning 2010Van gezondnaarbeter.RIVMͲrapportnr. 270061006
2010.
8. Kossoff EH, ZupecͲKania BA, Amark PE, BallabanͲGil KR, Christina Bergqvist AG, Blackford R,
Buchhalter JR, Caraballo RH, Helen Cross J, DahlinMG, Donner EJ, Klepper J, Jehle RS, Kim HD,
ChristianaLiuYM,NationJ,NordliDRJr,PfeiferHH,RhoJM,StafstromCE,ThieleEA,TurnerZ,Wirrell




9. Freeman J,Veggiotti P, LanziG, TagliabueA, Perucca E; Institute ofNeurology IRCCS C.Mondino
Foundation. The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res.
2006;68:145Ͳ80.




































26. O’DonoghueMF, Duncan JS, Sander JW. The National Hospital Seizure Severity Scale: a further
developmentoftheChalfontSeizureSeverityScale.Epilepsia.1996;37:563Ͳ71.
27. Dunn LM, Dunn LM. Peabody Picture Vocabulary TestͲIIIͲNL, Nederlandse versie door Liesbeth
Schlichting.HarcourtAssessmentB.V.,Amsterdam;2005.
28. Beery K. The BeeryͲBuktenica Developmental Test of VisualͲMotor Integration: VMI with































42. Oostenbrink JB,etal.Handleidingvoorkostenonderzoek,methodenen standaardkostprijzenvoor
economischeevaluatiesindegezondheidszorg.Collegevoorzorgverzekeringen2004.





















































Participants froma tertiaryepilepsy centerwere randomized intoKD (intervention)groupor
CAU (control)group. Seizure frequency,qualityof life (QALYs),health care costs,production
lossesofparentsandpatient& familycostswereassessedatbaselineandduringa4Ͳmonth
studyperiodandcomparedbetweentheinterventionandcontrolgroup.TheincrementalcostͲ






18.5%of theparticipants in theCAUgroup.There isa93%probabilityof theketogenicdiet
beingcostͲeffectivewhenlookingatthecostperresponder,ataceilingratioof€50,000based
onourcostͲeffectivenessacceptabilitycurve.We failed,however, tomeasureanybenefits in
termsofQALYsandtherefore,thecostperQALYrisehighaboveanyacceptableceilingratio.














time,about80,000 individualshaveepilepsy.2 In2004,the totalcostsofepilepsy in
Europewere€15.5billion,indirectcostsbeingthesinglemostdominantcostcategory
(€8.6billion).3In2011,intheNetherlands,thedirectmedicalcostswere€248million,
which is 0.3%of thehealth carebudget.4Although in themajorityof thepatients
epilepsy is treatablewith antiepilepticdrugs (AEDs), about30%of the cases suffer
fromintractableepilepsy.5Patientsarediagnosedashavingintractableepilepsywhen
theirseizuresarenotcontrolledaftertakingtwoormoredifferentAEDs.Patientswith
uncontrolledepilepsydependheavilyon informal care (family and friends), andon





surgerycanpotentiallybenefitfromaketogenicdiet (KD).TheKD isahighͲfat, lowͲ
carbohydrate diet that imitates themetabolic state of fastingwhilemaintaining a
normal number of calories. Body energy requirementswhile on a KD aremet by
lipolysis and ßͲoxidation of fatty acids rather than by the breakdown of
carbohydrates. The exact anticonvulsantmechanism of action of a KD has not yet
beenelucidated.6Currently,thescientificandclinicalattentionpaidtotheroleofthe
KD is negligible.7 Thismeans that a KD is often overlooked and underutilized as a
treatmentoptionforchildrenwithintractableepilepsy.Animportantreasonforthisis
that relatively few children and their parents can comply with the stringent diet.
Physiciansare,therefore,oftenreluctanttoinitiatethediet.Thebeneficialeffectofa
KD has been studied inmultiple observational studies8Ͳ16, reviews17Ͳ21 and in two
randomizedcontrolledtrials.22,23However,noneofthesestudieshasresearchedthe
costͲeffectiveness of the KD. Since resources are scarce, in current health care
decisionͲmaking,weneedtoprovetheeffectsoftheKDareworththeextracosts,24
to allow decisions to be evidenceͲbased.25 Economic evaluation is a method for
examining this tradeͲoff between costs and effects of comparative treatments. In
order to inform the decision makers, full (or good) economic evaluations are
necessary.Therefore,thistrialͲbasedeconomicevaluationresearchesthecostͲutility
andcostͲeffectivenessof theKDcomparedwithcareasusual (CAU) inchildrenand






The economic evaluationwas executed alongside a randomized controlled clinical
trial;detailsofthetrialdesigncanbefoundelsewhere.26Inshort,betweenJuly2010
andSeptember2014, subjectswere randomized toeither theKDor toCAUaftera
1Ͳmonth baseline period. Patients randomized into the KD group were followed
duringthe4Ͳmonthcomparativestudyperiodanda followͲupperiodof12months.
PatientsrandomizedintotheCAUgroupwerefollowedonlyduringthe4Ͳmonthstudy
period.The timelineof thestudy isgraphicallypresented inFigure7.1.This interim
analysisreportsthecostͲeffectivenessofthecomparativeperiodofthetrial, i.e.the
4ͲmonthstudyperiodwheredirectcomparisonbetweenKDandCAUispossible.This




















The patient population consisted of children and adolescents with intractable
epilepsy.Patientswereeligible toparticipate if theymet the following criteria:age
between 1 and 18 years; having uncontrolled seizures after trying two or more
appropriateAEDs(i.e. intractableepilepsy);noteligibleforepilepsysurgery;nofatty
acid oxidation disorders and related diseases; no diabetes and hyperinsulinism; no
prolongedQTͲtime syndrome; no hypercholesterolemia or hypertriglyceridemia; no
severe liver, kidney or pancreas diseases; no renal tubular acidosis; no severe
behavioraldisorder;nomalnutrition;notreatmentwithTopiramateorAcetazolamide





multidisciplinaryKD teamat theepilepsycenterKempenhaeghe in theNetherlands,
wheretheyreceiveddetailedinformationaboutthestudybeforegivingtheirconsent.










were continued without changes during the study period (except whenmedically
indicated).Thedieticiandecidedtogetherwiththeparentswhethertheclassicaldiet,
the mediumͲchain triglyceride (MCT) or a mixture of both diets was introduced.
ChildrenwhoweretubeͲfedwerealsotreatedwithKD.Thedietwasthenadjustedto
afluidversion.
After the 5Ͳday admission, weekly telephone meetings between parents and the
epilepsy nurse, and between parents and the dietician,were planned. Ketosiswas
checkeddailybytheparentsinurine(ifpossible)orthreetimesaweekinbloodviaa





















GenericQoLofboth thechildrenand theirparentswasmeasured.For thispurpose
the EuroQol instrument (EQͲ5D)27 and the EQͲ5DͲY version for children aged eight
years and older was used.28 The EQͲ5D health states were converted to a single
summary index between 0 and 1 (utility) by applying the Dutch utilityͲtariff.29 In
additiontothis,QoLwasalsoassessedbytheTAPQOL(TNOͲAZLPreschoolChildren’s











Costs were calculated from a societal perspective; therefore, protocolͲdriven
interventioncosts,otherhealthcarecosts,patientandfamilycosts,andproductivity




by a monthly cost diary,32 completed by the patient’s parent(s). Additional costs
consistedofparents’productivitylosses,basedonthehoursabsentfromworkdueto
theirchild’sepilepsyortheirownhealthͲrelatedproblems.






medicationwas taken intoaccount.Whendataonmedicationwerediverse, lowest
cost prices for the specificmedication were used. The cost of informal care was














  CAUgroup 1548.60b
Dietcosts(4months) Classicaldiet 0
  MCTdiet 2491.20b
  Tubediet 3476.40b
  Mixture 1246.60b
Ketosischeck Fingerpuncturedevice 21.73b
  Inblood(fingerpuncture) 2.02b








































on 1,000 bootstrap replications, as the data did not comply with the underlying
assumptionsofparametrictests.
Furthermore,thearithmeticmeanand95%nonparametricconfidenceintervalswere
calculated (1,000bootstrap replications) fordifferential costsandQALYsduring the
studyperiod.
Additionally, bootstrapping with Microsoft Excel 2010 was used to quantify the
uncertaintyaround the IncrementalCostEffectivenessRatio (ICER) (5,000bootstrap
replications). The ICERs were calculated by dividing the incremental costs by the
incrementalQALYs.The ICER represents the costofanadditionalQALYgainedand
was used to estimate the costͲutility of KD as opposed to CAU. The ICERs were
presented on a costͲeffectiveness (CEͲ)plane,which is divided into four quadrants.
The southͲeast quadrant represents the instanceswhere the intervention ismore




represents lesseffectiveand lesscostly interventions.24Atreatment isdeemedcostͲ
effectivewhenitisdominantorwhenthecostsperQALYarebelowaspecifiedceiling







A univariate and amultivariate sensitivity analysiswas performed to explore how
robusttheresultsweretochanges intheassumptionsuponwhichtheywerebased.
Firstly,weconductedtheeconomicevaluationfromahealthcareperspectiveinorder
to complywith the guidelines of other policy bodies.36 Secondly,we explored the
impactonthecostͲeffectivenessoftheKDbyvaryingthecostoftheinterventionand





study.Onepatientdroppedoutof thestudybefore randomizationcould takeplace




dissatisfaction regarding the randomization result, and three patients from the KD
group,duetospontaneousseizurereduction(onepatient)andprotocolviolation(two
patients),leaving48patientsintheITTanalysis.
Therewereno statisticaldifferencesbetween theKDandCAUgroupatbaseline in
utilities (bothTACQOL/TAPQOLandEQͲ5D)or in totalhealthcare,patient& family
and productivity losses. Therefore, baseline correction was assumed to be
unnecessary.DemographicdataandbaselineutilitiesarepresentedinTable7.2.
Outcomes
In total, 13 patients from the KD group (50%) and 4 patients from the CAU group
(18.2%) were responders (ш50% seizure reduction). Measuring utilities with the
EQͲ5DͲY seemed only possible in aminority of our patient sample.We, therefore,
used the utilityͲscores of the TAPQOL and TACQOL (ageͲdependent) to calculate
QALYsforthepatients.TheQALYsoftheparentswerebasedonutilitiesoftheEQͲ5D.
No significant differences were found in patients’ QALYs nor in parents’ QALYs




The CEͲplane for the costͲutility analysis, representing the uncertainty surrounding
thecostperQALY ratio, is shown inFigure7.2A.As theKD ismoreexpensive than
CAU (resp. €20,986 and €15,245) and (almost) equally effective in terms ofQALYs
(resp. 0.253 and 0.250),most bootstrapped ICERs lie in the northern part of the
CEͲplane(40%northͲwestand56%northͲeast).BasedonthecostͲutilityanalysis,the
KD isnotacostͲeffectivetreatmentoption.Figure7.2BpresentstheCEACbasedon








 KD N=26 CAU N=22
 N (%) N (%)
Female 8 (30.8) 13 (59.1)
Agemean(range) 7.8 (2.1Ͳ16.5) 8.1 (1.1Ͳ15.7)
Ageseizureonset(range) 2.4 (0Ͳ8) 1.9 (0Ͳ10)
Etiology  
Genetic 9 (34.6) 1 (4.5)
Structural 2 (7.7) 10 (45.5)
Unknown 15 (57.7) 11 (50.0)
FullscaleIQ  
<50 10 (38.5) 11 (50.0)
50Ͳ69 3 (11.5) 4 (18.2)
70Ͳ99 11 (42.3) 5 (22.7)
ш100 2 (7.7) 2 (9.1)
Behavioral/Cognitiveproblems  
ADHD 0 (0.0) 1 (4.5)
ADD 1 (3.8) 1 (4.5)
Autism 3 (11.5) 5 (22.7)
VNSatstartstudy 1 (3.8) 0 (0.0)
NumberofAEDsatstartstudy  
None 0 (0.0) 1 (4.5)
One 3 (11.5) 4 (18.2)
Two 12 (46.2) 8 (36.4)
Three 9 (34.6) 5 (22.7)
Four 2 (7.7) 2 (9.1)
Five 0 (0.0) 2 (9.1)
Diettype  
MCT 18 (69.2) Ͳ Ͳ
Classical 7 (26.9) Ͳ Ͳ
Mixture 1 (3.8) Ͳ Ͳ
PGT 6 (23.1) 5 (22.7)
Meanqualityoflife  
TACQOLorTAPQOL 0.77  0.75 
EQͲ5DͲyouth† 0.53  0.64 
NumberAEDstriedinthepast  
Three 3 (11.5) 4 (18.2)
Four 4 (15.4) 5 (22.7)
Five 9 (34.6) 3 (13.6)
Six 3 (11.5) 3 (13.6)
Seven 2 (7.7) 1 (4.5)
Eight 4 (15.4) 2 (9.1)
Nine 1 (3.8) 4 (18.2)
VNSinthepast 1 (3.8) 1 (4.5)








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































presented in the CEͲplane in Figure 7.3A. Now, most ICERs lie in the northͲeast
quadrant,indicatingthattheKDismoreexpensivebutalsomoreeffectivethanCAU
inchildrenandadolescentswithintractableepilepsy.Ataceilingratioof€50,000per













































admission to the epilepsy center, ignoring the telephone meetings with dietician

















































KD with CAU in children and adolescents with intractable epilepsy alongside a
randomizedcontrolledtrial.Theeconomicevaluationwasconductedfromasocietal
perspective.
TheKDgroup is,as farasnumberof responders is concerned,moreeffective than
CAU:resp.50%and18.2%,butfailstoshowanincreaseinQALYs.
Looking at the cost per responder, there is a 93% probability that the KD is costͲ
effectiveataceilingratioof€50,000.However,this4Ͳmonthanalysisshowsthatthe
KDisnotcostͲeffectivewhenincludingtheQALYasaprimaryoutcomeparameter,as
the corresponding ICERs of the costͲutility analysis rise high above any acceptable
ceilingratiointheNetherlands.
Our results are, however, sensitive to change, as can been seen in the sensitivity








from the scoresof theageͲdependentTAPQOLandTACQOL.The ‘utility’Ͳscoreswe
used to calculate QALYs, are, therefore, not preferenceͲbased utilities and
subsequentlynotcomparablewithother‘real’utilities.Secondly,astheTAPQOLand
TACQOL are ageͲdependent measures, our used utilityͲproxies consist of a




would be successful inmeasuring an increase inQALYs relating to the number of
respondersifwehadapreferenceͲbasedgenericqualityoflifeinstrumenttobeused
in children of all ages. Half of the participants in our study were children and
adolescentswithcombinationsofsevereintellectualandphysicaldisabilitiesforwhich
measuring quality of life is an overall challenge.37 On the other hand, being a
respondermaynotbeenoughtogainQoL.
Thethirdlimitation,istheshorttimehorizonofthestudywhichcanbethereasonfor
our inability tomeasure change inQALYs or costs. This analysis compares the KD
groupwiththeCAUgroupoveraperiodof4months.Althoughalongercomparative
periodwouldbepreferable,thiswasnotpossibleduetoethicalconsiderations.The
significantdifferences in costs thatwe foundwere fully related to the intervention






costs reported are (partly) related to the protocol of the tertiary epilepsy center
Kempenhaeghe.
Until now, two otherRCTs comparing KDwith CAU can be found in thepublished
literature.22,23ComparingtheresultsofthisstudywiththosefromtheRCTreportedby
Neal et al.22 and Sharma et al.23, showed that we found a higher percentage of
responders(50%)intheKDgroupcomparedtoNealetal.(38%)andaslightlylower
percentageof responders than Sharma et al. (52%).Comparing thedifference,our
numberof ‘responders’ (18.5%) inthecontrolgroupwas largerthanthosereported
byNealetal.(6%)orbySharmaetal.(11.5%).OurcostͲutilityresultsareinlinewitha
recentlypublishedmodelͲbasedeconomicevaluationinwhichtheKDiscomparedto
vagus nerve stimulation (VNS) and CAU.38 Based on the results of this costͲutility
Markov model, neither KD nor VNS are costͲeffective options compared to CAU
(€346,899 and €641,068 per QALY, respectively). Furthermore, Mackay et al.
estimated the costs of three and 12months KD to be AUS$3,879 and AUS$7,275,
respectively.39
Despite the reported limitations, this study presents evidence of an economic
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of the treatment strategiesKD,VNSandCAU, fromahealthcareperspective.Thebasecase
consideredchildrenwith intractableepilepsy (i.e. twoormoreantiepilepticdrugshad failed)













therapies. However, these treatment options should not be ignored in the treatment for
intractableepilepsy in individualorspecificgroupsofpatients.There isagreatneed forhigh
qualitycomparativestudieswithlargepatientsampleswhichallowforsubgroupanalyses,longͲ
termfollowͲupperiodsandoutcomemeasuresthatmeasureeffectsbeyondseizurefrequency











seizures is surgically removed. If resective surgery failsor isnotanoption,children
with intractableepilepsy inparticular canpotentiallybenefit fromaKetogenicDiet
(KD).2TheKDisahighͲfat,lowcarbohydratedietthatimitatesthemetabolicstateof
fastingwhileremainingnormocaloric.BodyenergyrequirementswhileontheKDare
met by lipolysis and BͲoxidation of fatty acids rather than by the breakdown of
carbohydrates.Anothertreatmentoptionforchildrenwithintractableepilepsycould
bevaguenerve stimulation (VNS).VNS isapacemakerͲlikedevice that is implanted
subcutaneouslyintotheupperpartofthechestwithaconnectingwirerunningfrom
the stimulator to an electrode that is attached to the vagus nerve.3 Once the
stimulator is activated, electrical pulses will be generated at regular intervals
dependingontheanticonvulsanteffectandonthepatients’tolerance.




is increasingly important to examinewhether benefits outweigh costs. The use of
decisionmodeling in economic evaluation is a powerful tool for investigating this
tradeͲoffbetweencostsandeffectsofcomparativetreatments.Modelingallowsthe
synthesis of all available evidence from different sources.Modeling alsomakes it
possible to include longͲterm costs and benefits in the analysis.7 This is important
because the impact of epilepsy (treatments) on patients’ lives, seizures, and costs
extendsbeyondthestudyperiodofmostclinicalstudies.
TheprimaryaimofthepresentstudyistouseathreeͲarmdecisionanalyticalmodel












The model was built in Microsoft Excel 2010 following established economic
evaluationstateͲtransitionmodelingguidelines.6Costsandeffectsweremodeledwith
atimehorizonof5years.
Figure 8.1 is a graphical representation of the model. In the first cycle, the
hypothetical cohort started on KD, VNS or stayed on CAU. After three months,




entered one of the health states: 1) seizureͲfree, 2) improvement (50% ormore
seizure reduction), and 3) no improvement (less than 50% seizure reduction). The
absorbing state was ‘death’, either due to Sudden Unexpected Death in Epilepsy



















Inorder to validate themodel8 and to retrievebackground informationneeded to
furtherdevelopthemodel,weorganizedtwoexpertmeetings.Inthefirstsession,the
decisionproblemwasoutlinedandassumptionsrequiredtodeterminethestructure
of themodelweregenerated. In thesecondsession, themodeland its inputswere
validated.Theforemostcriterionforexpertselectionwastheextentoftheirexpertise
andexperiencewithintractableepilepsyinchildrenand/orresearchexperienceinthe
fieldofefficacy and costͲeffectiveness.9During the firstmeeting threeneurologists
(DL, AL, and MM), one behavioral scientist (AA) and one HTA expert (RdK)
participated.During the secondmeeting, three neurologists (DL,AL, andMM) and
threeHTAexperts(JG,DPandRdK)tookpartinthediscussion.




















inwhichKDwas comparedwithCAU,10,11 and threeRCTs that comparedVNSwith
CAU.12Ͳ14No RCTs comparing KDwithVNSwere found. Since two VNS studies,14,15
partially reported on the same patients,we combined these studies to correct for
doublecounting.TheseRCTsandtheir longͲtermfollowͲupstudies16Ͳ19wereusedto
estimateprobabilitiesregardingefficacyandsafety.Pooledproportionanalyseswere








 Basecase12months  
 Estimatedvalue SE Distribution Source
Ketogenicdiet    
1stcycle    
ProbabilitySF 0.048 0.041 Beta (9,10,17)
ProbabilityIMPR 0.345 0.061 Beta (1Ͳ3)
ProbabilityNOIM 0.607 0.104 Beta (1Ͳ3)
2ndcycle    
ProbabilitySFtoIMPR 0.500 0.289 Beta (17)
ProbabilityIMPRtoNOIM 0.162 0.060 Beta (17)
Probabilityothertransitions 0.000 Fixed  (17)
3thcycle    
ProbabilityIMPRtoSF 0.099 0.052 Beta (17)
ProbabilityIMPRtoNOIM 0.065 0.043 Beta (17)
Probabilityothertransitions 0.000 Fixed  (17)
4thcycle    
ProbabilityIMPRtoSF 0.099 0.057 Beta (17)
ProbabilityIMPRtoNOIM 0.065 0.047 Beta (17)
Probabilityothertransitions 0.000 Fixed  (17)
5ndͲ20thcycle    
Probabilitytransitions 0.000 Fixed  EM
VagusNerveStimulation    
1stcycle    
ProbabilitySF 0.013 0.007 Beta (11Ͳ13)
ProbabilityIMPR 0.225 0.032 Beta (11Ͳ13)





 Basecase12months  
 Estimatedvalue SE Distribution Source
2ndcycle    
ProbabilitySFtoIMPR 0.006 0.005 Beta (12,15,16,18)
ProbabilitySFtoNOIM 0.003 0.004 Beta (12,15,16,18)
ProbabilityIMPRtoSF 0.003 0.003 Beta (12,15,16,18)
ProbabilityIMPRtoNOIM 0.008 0.010 Beta (12,15,16,18)
ProbabilityNOIMtoSF 0.015 0.012 Beta (12,15,16,18)
ProbabilityNOIMtoIMPR 0.015 0.012 Beta (12,15,16,18)
Probabilityothertransitions 0.000 Fixed  (12,15,16,18)
3thcycle    
ProbabilityIMPRtoSF 0.011 0.010 Beta (12,15,16,18)
ProbabilityIMPRtoNOIM 0.011 0.010 Beta (12,15,16,18)
ProbabilityNOIMtoSF 0.006 0.005 Beta (12,15,16,18)
ProbabilityNOIMtoIMPR 0.034 0.021 Beta (12,15,16,18)
Probabilityothertransitions 0.000 Fixed  (12,15,16,18)
4thcycle    
ProbabilityIMPRtoSF 0.011 0.010 Beta (15,16,18)
ProbabilityIMPRtoNOIM 0.011 0.010 Beta (15,16,18)
ProbabilityNOIMtoSF 0.006 0.005 Beta (15,16,18)
ProbabilityNOIMtoIMPR 0.009 0.008 Beta (15,16,18)
Probabilityothertransitions 0.000 Fixed  (15,16,18)
5thcycle    
ProbabilityNOIMtoSF 0.005 0.002 Beta (15,16)
ProbabilityNOIMtoIMPR 0.006 0.019 Beta (15,16)
Probabilityothertransitions 0.000 Fixed  (15,16)
6thcycle    
ProbabilityNOIMtoIMPR 0.009 0.008 Beta (16)
Probabilityothertransitions 0.000 Fixed  (16)
7ndͲ20thcycle    
Probabilitytransitions 0.000 Fixed  EM
CareasUsual    
1stcycle    
ProbabilitySF 0.008 0.008 Beta (9)
ProbabilityIMPR 0.075 0.028 Beta (9)
ProbabilityNOIM 0.917 0.028 Beta (9)
2ndͲ20thcycle    
Probabilitytransitions 0.000 Fixed  EM
Withdrawal    
ProbabilitywithdrawalKD 0.128 0.025 Beta (9,10,17)
Ͳduetosideeffects 0.536 0.153 Beta (9,10,17)
Ͳduetootherreasons 0.464 0.153 Beta (9,10,17)
ProbabilitywithdrawalVNS 0.016 0.007 Beta (11,14)
Ͳduetosideeffects 0.709 0.152 Beta (11,14)
Ͳduetootherreasons 0.291 0.152 Beta (11,14)
Probabilitywithdrawal+removalVNS 0.008 Fixed  (11,14)









Annual ageͲspecific allͲcausemortality rateswere based onDutch life tables20 and
transformed into threeͲmonthmortality rates. SUDEP rateswere added to the allͲ
causemortalityrates,basedonanextensiveliteraturereviewbyShorvonandTomson
(2011).21 Complications regarding VNS implantationwere included in themodel in
caseswhen removal of the devicewas necessary. Side effects due to antiepileptic
drugswerenot included in themodel,yetassumed tobe similar forallpatients in
each treatment arm. Other complications, such as gastrointestinal complaints and
hoarseness,werenot incorporated in themodel; there aremany,with generally a
limitedorshortͲterm impactonqualityof lifeorcosts.PatientsonKDwould follow
the dietary treatment for amaximum of 24months, after this period they were




QualityͲadjusted life years (QALYs) were the primary measure of effect. The
combinationofutilityscoresand lifeexpectancyallowsforthecalculationofQALYs,
andcostperQALY ratios.Utilitywasconsideredasasingle indexonascale from0
(representingdeath)to1(representingfullhealth).Aliteraturesearchidentifiedfour
studies that computedutility values for an appropriatepopulationof subjectswith










were obtained in the expertmeetings, asmost of themwere not available in the
literature.Consensuswas reachedondruguse, the frequencyof contactswith the
nurse practitioner, neurologists and other specialists related to patientmonitoring
and switching treatments, and treatment of adverse effects. Epilepsy related
hospitalizationswereobtained from the literature.27The initiationcostsofKDwere
basedonthestandardizedprotocolofthetertiaryepilepsycenterKempenhaeghe in
TheNetherlands.Thesecostsconsistedofa5Ͳdayadmission to theepilepsycenter,
visits of the neurologist, pediatrician, dietician and epilepsy nurse, and laboratory
costs.Costs related to theKDwere vitamin anddiet supplements, and keto sticks.




diet, 15% the classical diet and 5% diet via tube feeding. VNS implantation costs




of side effects due to antiepileptic drugswere not taken into account; theywere




 Estimatedvalue Range Distribution Source
Resourceuse(volumes)     
Seizurefree     
Ͳnumberofneurologistvisits 0.25 0.0Ͳ0.50 BetaPERT EM
Ͳnumberofseizurerelatedhospitalizations 0.275 0.0Ͳ0.50 BetaPERT (26)
Improvement     
Ͳnumberofneurologistvisits 0.5 0.25Ͳ0.75 BetaPERT EM
Ͳnumberofhospitalizations 0.625 0.50Ͳ0.75 BetaPERT (26)
NoImprovement     
Ͳnumberofneurologistvisits 1.0 0.75Ͳ1.25 BetaPERT EM
Ͳnumberofhospitalizations 1.65 1.0Ͳ2.0 BetaPERT (26)
Unitcosts(€)     
InitiationKD 4,542.22 Fixed  EM,PC,(27)
MCTdiet 2,008.71 Fixed  EM,PC,(27)
Tubediet 2,666.70 Fixed  EM,PC,(27)
Medicalvitaminsupplements 105.55 95Ͳ116 BetaPERT PC
Regularvitaminsupplements 35.31 19.80Ͳ50.40 BetaPERT PC
Ketosticks 20.68 11.88Ͳ26.98 BetaPERT PC
Outpatientvisittospecialist 78.12 Fixed  EM,PC,(27)
Visittoepilepsynurse 109.33 Fixed  PC
Hospitalizationperday 497.67 Fixed  EM,PC,(27)
VNSimplantation 16,889.98 Fixed  EM,PC,(27)
RemovalVNS 2,700.00 Fixed  PC
UtilitiesperHealthstate     
Seizurefree 0.935 0.754Ͳ1.00 BetaPERT (21,23)
Improvement 0.790 0.51Ͳ1.00 BetaPERT (21,23)
NoImprovement 0.660 0.461Ͳ0.78 BetaPERT (21,23)
Withdrawal 0.400 0.32Ͳ0.50 BetaPERT (21,23)
SUDEPmortalityperHealthstate     
Seizurefree 0.00028 Fixed  (20)
Improvement 0.00148 Fixed  (20)




Costs andeffectsweremodeledwith a timehorizonof12months and at5 years.
Incremental costͲeffectiveness ratios (ICERs) were calculated by dividing the




additionalQALY gained andwasused to estimate the costͲeffectivenessofKD and
VNSasopposedtoCAU.Subsequently,theICERofKDopposedtoVNSwascalculated.






represents lesseffectiveand lesscostly interventions.29Atreatment isdeemedcostͲ
effectivewhenitisdominantorwhenthecostsperQALYarebelowaspecifiedceiling
ratio. InTheNetherlands, an informal ceiling ratiobetween approximately€20,000
and €80,000 per QALY exist, depending on the burden of disease.30 Furthermore,
CostͲEffectiveness Acceptability Curves (CEACs)were calculated.29 CEACs show the
probabilitythatatreatmentiscostͲeffective,givendifferentceilingratios.Finally,the
number of responding patients and incremental cost per responding patientwere
calculated.
Sensitivityanalysis
Uncertainty surrounding input parameter estimates, such as efficacy, utilities and
costs, ischaracterizedby the limitationsorabsenceofevidenceavailable to inform
inputparameters.Probabilisticsensitivityanalysiswasusedtocapturetheuncertainty
in the input parameters. Thismeans thatwe assigned distributions to themodel
parameters.31Uncertainty inefficacy transitionprobabilitieswasexpressedasBetaͲ
distributions,while uncertainties in cost data and utility valueswere expressed as
BetaPERTdistributions.
Adistributionof the incremental costsandbenefitswasdeterminedby samplinga
valuefromeachinputparameterdistribution,calculatingtheresultswiththemodel,
then repeating this process 1000 times. The results were presented with a point
estimateand95%confidence intervals,aswellasa jointͲdistributionof incremental
costsandQALYsonacostͲeffectivenessplane,illustratingtheuncertaintysurrounding
theestimatesofincrementalcostsandQALYs.
Deterministic sensitivity analysis was used to investigate the impact of the cost
differencebetweendifferentvariantsoftheKD.AlthoughNealetal.(2009)18showed
no difference in effects between the classical KD variant and theMCT KD variant,
there ishowever, a costdifferencebetween these variants. Thebase case analysis
assumesthat80%ofthepatientswillbetreatedwiththeMCTvariantand5%viatube
feeding.AsthenumberofpatientsontheMCTishighlydependentontheinstitute’s











expectedhealth care costswere€14,036perpatientover12months.VNS therapy
yielded less responders (27%) and less QALYs (0.688) and was more expensive
(€19,922).ComparingKDwithVNS,KDdominatedVNSintermsofcostperQALYand
per responder, asKD is less costlyandmoreeffective.CAUwas the leasteffective
(0.662 QALYs and 8% responders) and also the least expensive therapy (€3,306).




 Expectedcostsin€(95%CI) ExpectedQALYs(95%CI) ICER(€perQALY)
At12months       
KD 14,036 (13,310Ͳ14,735) 0.693 (0.579Ͳ0.747) KDͲVNS Dominant
VNS 19,922 (19,391Ͳ20,259) 0.688 (0.571Ͳ0.742) KDͲCAU 346,899
CAU 3,306 (2,405Ͳ3,851) 0.662 (0.536Ͳ0.710) VNSͲCAU 641,068
At5years       
KD 30,935 (27,610Ͳ33,347) 3.338 (2.823Ͳ3.612) KDͲVNS 11,378
VNS 31,581 (29,233Ͳ33,356) 3.395 (2.876Ͳ3.747) KDͲCAU 86,025






responders (42%). The expected health care costs were €31,581 per patient. KD
yielded fewerQALYs (3.34), less responders (30%) andwas slightly less expensive
(€30,935).The ICERofVNScomparedtoKD is€11,378perQALYgained (Table8.3).













































CAU at 1 and 5 year, (C) KD compared to VNS at 1 and 5 year.  ICER, Incremental Cost

























































no hospitalization at 12months, and (D) sensitivity analysiswith 100% of patients on the
classicalKDvariant (noMCT)andnohospitalizationat5years.QualityAdjustedLifeYears;













care costsof classicalKD at12months are€8,297.Additionally,wedecreased the
costsoftheclassicalKDbyassumingthatnohospitalizationwasnecessarytoinitiate
thediet, resulting ina totalhealthcarecostsof€6,550at12months.Foraceiling
ratio of €20,000 and €80,000 CAU still has the highest probability of being costͲ
effective(100%resp.91%),followedbyclassicalKD(0%resp.9%)andVNS(0%resp.
0%) (Figure 8.3C). The total health care cost of KD at 5 yearswhen 100% of the
patientsusestheclassicalKD,are€18,550.Foraceilingratioof€20,000,againCAU








as the corresponding ICERs rise well above any acceptable ceiling ratio in The




the initial (high) costs of the surgical procedure associatedwithVNS including the
device itself are spread over 5 years. Therefore, the expected costs becomemuch




From aneconomicperspective andbasedon these results,one couldargue that a
childwith intractableepilepsyshouldfirstbetreatedwiththeKDbeforetryingVNS;




Our results are however, sensitive to change, as can been seen in the sensitivity
analyses,whereweincreasedthepercentageofclassicaldietusersfrom15%to100%
and simultaneously lowered the KD initiation costs by assuming that no
hospitalization is required. This resulted in a higher probability for KD to be cost
effectiveat12monthsandat5years.Thisimplicatesthatincountrieswhereonlythe
classicalvariantoftheKDisofferedandinitiatedwithouthospitalization,thatthereis
ahigherprobabilitythattheKD isacostͲeffectivetreatmentoption inthe longͲterm
compared toVNSandCAU (seeFigure8.3B).However in countrieswhere theMCT
variant of the diet is offered, there is a higher probability that the VNS is a costͲ
effective treatment option in the longͲterm compared to KD and CAU (see Figure
8.3D).
Everystudyhassomestrengthsandweaknesses.Oneofthestrengthsofthisstudyis
thatwe constructedamodel thatenabledus todirectly compare the longͲterm (5
years)costsandeffectsofthreeclinicallycompetitivetreatmentoptions,despitethe
lack of comparative studies between all scenarios. Based on such evaluations,
decisionsaremadeaboutthe implementationand/orreimbursementoftreatments.
Furthermore,wevalidatedthestructureandtheinputparametersofthemodelwith
a teamofexperts fromdifferent fields.Oneof themajor limitationsof thestudy is
thatwewereunabletopredicttheoutcomesovera longertimehorizon. Ideally,an
economicmodelofepilepsy shouldhavea lifetimehorizon inorder to capture the
relevant outcomes in terms of the mortality and morbidity associated with this




however, extremely difficult to estimate without a strong body of high quality
literature. Therefore, themodelwas initially estimatedwith a time horizon of 12
months.We felt,however, sufficiently confident to calculate the costͲeffectiveness
overa longerperiod, i.e.5years.Basedon theopenͲlabelextensionphasesof the
RCTs,12monthsofdatawereavailablefortheKDarm18and18months’dataforthe
VNS arm.17 In all treatment options, we remained conservative by assuming
transitionswould not change after the time horizon of the available clinical data.
Second limitation is thatweusedmainlyDutchcosts.Ascosts inother jurisdictions
willbedifferent from theDutchsituation,our resultscouldbe lessgeneralizable to
other health systems. Given our detailed presentation of themodel and its input
parameters, interested readers can assess the transferabilityof the results to their
specificsituation.31
Third limitationof thestudy is thequantityandqualityof thesynthesizeddata.We
usedclinicaldataofpublishedRCTsandtheiropenͲlabelfollowͲupperiodswhichare





we solelyhad to relyon expertopinions. Finally, inorder topresent the costsper
QALYwehad toallocateabsoluteutilities to relativehealth states,as themodel is
depending on the outcome measures used in clinical trials (i.e. >50% seizure
reduction).However,a reduction in seizure frequency from two toone seizureper
day is probably, in terms of utilities, not the same as a reduction from 50 to 25
seizures per day.Moreover,modeling always involves simplification, and amodel
should not be faulted because available data do notmeet the ideal standards of
scientificevidence.32
Our results show that thebenefitsofKDandVNS fail tooutweigh the costsof the
therapies.However,itwouldbeclinicallyincorrecttostatethattheseoptionsshould
be ignored in the treatment of intractable epilepsy. Dugan and Devinsky (2013)33
commented on themost recent VNS guidelines,34 by saying that in the view of a
criticalreviewerthereisonlyweakscientificevidenceontheeffectivenessofVNS.In
the view of a clinician, however, VNS has much to offer. Apparently there are,
althoughnot reported in the includedRCTs,other factorsbeyondseizure frequency




of life. Furthermore, clinicians are in desperate need to offer an alternativewhen
antiepilepticdrugsarefailing inthisdevastatingdisorder.The(further)development










with thebestavailableevidenceunder conditionsofuncertainty, thanwithout any
evidenceatall.Althoughour results shouldbe interpretedwithgreatcaution, they
are potentially meaningful for clinicians and policymakers. From an economic
viewpoint, neither VNS nor KD is a costͲeffective option compared to CAU at





which allow for subgroup analyses, longͲterm followͲup periods and outcome
measures thatmeasureseffectsbeyond seizure frequency (e.g.qualityof life). It is
important that when new evidence becomes available, reassessment of the costͲ
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to provide insights into the general aim, this thesis is structured around three
researchquestions.Thischapteropenswithapresentationofthemainconclusionsof
the researchquestions. Then somediscussion themes regardingHealth Technology








and the use of (new) interventions. It is, therefore, important that outcomes in
different fields are comparable. By estimating health benefits in terms of Quality
AdjustedLifeYears(QALYs),itistheoreticallypossibletocomparedirectlythecostsof
achieving such health benefits. Utilities are essential in order to calculate QALYs;
however,utilityestimatesareseldomavailable.EspeciallyinthecaseofmodelͲbased,






as seizure reduction. A uniform understanding of the implication of a seizure
reduction on a patient’s health state utility is lacking. Many studies report an
association between seizure frequency with poorer QoL1,2; others have found a
significant association onlywhen patients became seizureͲfree3 or have not found
such an association at all.4,5 Furthermore, some others argue that in case of
intractableepilepsy,seizurefrequencymaybe less importantthanpatientͲperceived
seizureseverityorsideͲeffectsduetoantiepilepticdrugsinpredictingQoL.6,7
To obtain more insight into factors affecting QoL, we researched (chapter 2)
preferencesforthreeclinicaloutcomemeasures:seizurefrequency,seizureseverity,







evaluations. Until now, this is the best ‘bridge’ between clinical epilepsy outcome
measures and HTA relevant outcomemeasures. The study described in chapter 2
showed that seizure frequency, seizure severity and sideͲeffects have a significant
impact on QoL. Furthermore, it is concluded that seizure severity is the largest
predictorofQoL.The studywas conducted froma societalperspective.Hence, the
general population was provided with a webͲbased questionnaire and asked to
expresstheirpreferencesforepilepsyhealthstates.
Onemayconsider ita logicalchoicetoaskpatients inspecifichealthstatestovalue
theirownhealth.Whilethisindeedhasbeenadvocated8,itisrelativelyunusualtodo
so, for several reasons.Firstly,patientsmayadjust to theirpoorhealthandhence,
theyvalue theirhealthstatebetter thannonͲpatients9Ͳ11 (i.e.adaptation);however,
other observations also exist.12,13 Second and third arguments used to obtain
preferences from the general public are: II) the societal perspective14, and III) the
insurance principle.15 These arguments are considered to be sufficiently convincing
and supportive of the view that the value of a health state should solely be
determinedbygeneralpublicpreferences.Othersarguethatcompletelydisregarding
patientpreferencescannotbebasedontheargumentsputforward inthe literature
and show that using societal preferences may result in either higher or lower
estimatesofcostͲeffectivenesswhencomparedtousingvaluesobtained inpatients.







to work19, what telephone service a customer decides to purchase20, among
numerousotherapplications.Inrecentyears,therehasbeenagrowinginterestinthe





used previously to estimate preferences of patients with epilepsy regarding sideͲ
effects of antiepileptic drugs (AEDs).23 Knowledge on patients’ preferences can be
usedforthecreationofnewinterventionsortreatments,andcanbeinformativefor
clinicians in the decisionͲmaking process. It is, however, unclearwhether patients’
preferences regarding treatments and their potential adverse effects are always
considered in theclinicaldecisionͲmakingprocess,which is, in the fieldofepilepsy,








to what extent important attributes of diagnostic procedures in epilepsy affected
preferences for a procedure, and to determine the relative importance of these





are possible. Beforehand, however, itwas not thought that itwould be themost
influentialfactorindeterminingpatients'preferences.
Not all results presented in this chapterwere straightforward or in line with the
expectationsaͲpriori.Patients’preferencesmay sometimesbe included indecisionͲ







medicalcosts in2011were€248million,which is0.3%of thehealthcarebudget.27
Themain costdriver ishealth careprofessional visitsandhospitalizations including
diagnosticprocedures (e.g.MRI,EEG),accounting foralmosthalfof the totaldirect
medical costs (€122 million). Institutionalized patients are the second main cost
driver, accounting for €73.6million and the thirdmain cost driver is the cost of
medication (€36.5million).27Although epilepsy is adiseasewith ahighmedication
usage,thecostsofmedicationsaccountfor lessthan15%ofthetotalmedicalcosts.
However,whenpatientsneedtochangetheirmedicationsorexperience (any)sideͲ
effects theywill visit their attending physician or the hospital, resulting in higher
actualmedicationcosts.
ThemajorityofmedicationsusedinepilepsyareAEDs.Thereare(theoretically)many
AEDs available; currently, approximately 25 different AEDs, which can be very
successful in controlling seizures in about 70% of the patients; sideͲeffects are,
however, common. In order accurately to reflect the total management costs,
pharmacoͲeconomic analyses should include the evaluation of costs related to
negativeoutcomesofpharmacotherapy,suchasadversedrugreactions.Thecostsof









motor problems, gastrointestinal complaints, cognition, visual,mood and behavior,
cosmeticorsleepingproblems.31Subjectively reportedcommonsideͲeffectsarenot
likely to induce such very expensive hospitalizations; however, costs of (over the
counter)medicationandvisitstothegeneralpractitioner,specialistorparamediccan
aggregatetohighcosts,especiallywhensuchsideͲeffectsarechronic.Inchapter4we
explored the societal costs of common, subjectively reported, sideͲeffects and
concluded that the overall societal costs due to sideͲeffects in patients from the
tertiary epilepsy center amounted tomore than €20,000 per patient per year, of
which almostaquarterwas related todirectmedical costs (€4,475).The advice is,
therefore,thatcostsofsideͲeffectsshouldbeconsideredineconomicevaluationsof
pharmacotherapy. The above estimation was solely related to sideͲeffects due to
AEDs; other treatments, however, such as the ketogenic diet or vagus nerve












rising costs, solidaritywill comeunderpressure.Mostpeople considergoodhealth
caretobeoneofthemost importantprovisionswhichrequiressubstantial funding.
Younger generations with an average wage with no or low usage of health care
wonderifthereisaproperbalancebetweenpayingforhealthinsurancenowandthe
consumptionofhealthcare later.A lackofconfidence inandresponsibility towards
the solidarity principle of our health care system has occurred due to everͲrising
healthcareexpenditures,insurancepaymentsandincreaseddeductibles.Tointerrupt
thisdownwardspiral,weneedtomakechoicesinhealthcare(seealsochapter1).





toprioritize interventions inascarceenvironment.As introduced inchapter1,there
areseveralsteps involved indeterminingwhetherornota (medical) intervention is
more costͲeffective than usual care in economic evaluations. For a meaningful





inaparticular topicarea,appraise theirqualityandsummarize their resultsusinga
scientific methodology.33 In total, 12 articles were included, all presenting full
economicevaluationsofaddͲonAEDs.Theoutcomemeasuresused in the included
articles differed (e.g. cost per seizureͲfree day, per responder, per seizureͲfree
patient,perQALY),makingcomparisondifficult.The largedifferences incostsfound
betweenstudiesislargelyduetotheperspectiveoftheeconomicevaluationandthus
the cost factors taken into account. For example: the results ranged from £761 to
£154,831perQALY, for respectively, zonisamide followedby lamotrigine compared
with levetiracetam followed by lamotrigine and, topiramate compared with
lamotrigine.Furthermore,thecostsperresponderrangedfrom€954perpatientwith
50% seizure reduction to £5,301 per seizureͲfree patient. A certain amount of
heterogeneity between the economic evaluations is unavoidable, because of the
multiple choices availablewhen defining parameters of economic evaluations (e.g.
designs,outcomemeasures,patient samples, etcetera, see also chapter1).On the
other hand, other areas of heterogeneity can be avoided, simply by following
standardeconomicresearchmethods.34Ͳ37




studieswere conductedwhich differedmethodologically. First of all, a trialͲbased
economicevaluationwasconducted(theKOEKͲstudy)inwhichtheKDwascompared
with care as usual (CAU) in a RCT (chapter 7). Calculating the cost perQALY at 4Ͳ
months resulted in an unfavorable outcome for KD compared to CAU (i.e. KDwas
more costly and generated an equal amount of QALYs compared to CAU, see
chapter7). However, comparing the number of responders (i.e. ш50% seizure
reduction)showedasignificantdifferenceinfavorofKD.
Secondly, a modelͲbased economic evaluation with QALYs as primary outcome
measurewasconducted,inwhichtheKDandVNSwerecomparedwithCAU(chapter
8).Here,theestimatedQALYswerebasedonpublishedutilities,(partly)suitablefor
our clinicalhealth states.Atoneyear followͲup,neitherKDnorVNS seemed tobe
costͲeffectiveatanygivenceilingratio.However,boththerapiesappearedtobemore
















The conclusion that a clinicianwould reach, and that apolicyͲmaker shouldmake,






Studies investigating the uptake of HTAͲstudies in clinical practice found that this
uptake is generally limited.40Ͳ43Most of these studies have also revealed thatwith
respect to evidenceͲbased research, clinical aspects have a greater influence on
clinical decisionͲmakers. HTA research, including economic evaluations, are often
considered to be of secondary importance. Furthermore, the lack of economic
evaluationsinthefieldofepilepsycanbeattributedtobothlimitedfundingforsuch
studies36,and the fact thatevaluationmethodsare insufficientlydeveloped todeal





Our health care systems are continuously being offered new drugs, devices and
procedures,mostofwhichproducehealthbenefits.Thesebenefits,however,often
entail considerable additional costs for society; and as health care resources are
limited,effortsaremadetoprioritizetheacquisitionandtheuseoftechnologies. In
order tobeable toprioritizehealthcare, it is important thatoutcomesofdifferent
health conditions can be compared. Since it is difficult to compare very different










impact on QoL5,44,45, the clinical community has continued to focus primarily on
seizuresandtheirtreatment.
In Chapter 7 we found a significant difference in the number responders in the
ketogenicdietgroupcomparedwith thecareasusualgroup.Wedidnot,however,
findanydifferenceinQALYsbetweenthetwogroups.Findingdiscrepanciesbetween
themain clinical epilepsy outcomemeasure (i.e. ш50% seizure reduction) and the
mainHTAoutcomemeasure (i.e.QALYs) isnotamotivatingbasis in theattempt to
bring the twoworlds closer together. So how is it possible thatwe found such a
discrepancybetweentheBTAandtheclinicalmeasure? Isbeingarespondernotan
indicator for increased QoL in patients with intractable epilepsy? Or is the
measurement instrument we used insensitive to clinical improvements in these
patients?
On the one hand, the critical attitude of clinicians towards theQALY is not totally
groundless.BesidesthediscrepancybetweentheclinicalandHTAoutcomemeasures,
there are more caveats to the measurement of the QALY in epilepsy. Firstly, a







namely, utility (the strength of preference for a certain health state). Onemight
expectthedifferences inresultsfoundbetweenthe instrumentsto leadtoacritical




These resultshighlight anunsatisfactory stateofmeasurement theory andpractice
withrespecttothegenericpreferenceͲbasedutilityinstrumentswhichmeasureQoL.
Economistswhohavecreatedthe instrumentshavefocusedalmostexclusivelyupon
thederivationofthe ‘utilityͲtariff’48fromthegeneralpopulation,which is important
for the second part of the instrument. Despite the existence of wellͲestablished
psychometricmethods,theyhavelargelyignoredthereliabilityandvalidityofthefirst
part of the instrument, that is, the questionnaire used to obtain the health state
descriptionfromapatient.Asaconsequence,theprecisionofclinicalmeasurementin






Secondly, the sole functionofaQALY is toenabledecisionͲmakers to compare the
costofverydifferenthealthconditions.Toachievethis,allexistingQALYsmusthave
beenvaluedequally;however,thevalueaccordedtothemvarieswithcircumstance.
For example, there is evidence that the value given to a health state differs per
methodused(e.g.TTO,SG,orVAS)49Ͳ51,(methodological)context(e.g.leadͲtimeand




solution.Researchover thepast20yearshasdemonstrated thatchanges inseizure
rates among patients with intractable epilepsy are onlymodestly correlated with
QoL.53Ͳ55AsPeruccaandcolleaguessuggest,“thelackofinvestigationstowardsother
clinicalfactorscanbeascribedtohistoricalbeliefthatseizurefrequencyisthemajor
determinantofQoL”.7 There arepossibleother clinical factors,or evennonͲhealth
factors that are strongly related toQoL. Patientswith epilepsy have a significantly
higher prevalence of psychological and psychiatric comorbidity comparedwith the
populationwithoutepilepsy.56Forexample,the lifetimeprevalenceofdepression in
patientswithepilepsyrangesfrom29%Ͳ50%57;therangeinthegeneralpopulationis
16Ͳ22%.58,59 Furthermore, social and interpersonal stresses that a patient with
epilepsyencounters through stigma, social isolationandunemploymentalsohasan
impactontheirQoL.60,61SpecificriskfactorsassociatedwithQoLinchildrenconsistof
avarietyofclinicalandfamilyfactors.62Asthereisgrowingevidencethatpsychosocial
factors and poormental health have the greatest impact onQoL in patientswith
epilepsy5,63,64, Elliot and Richardson65 opt for a shift from the biologicalͲbiomedical
modeltoabioͲpsychosocialmodelinordertounderstandQoL.Furthermore,patients
with intractable epilepsy commonly suffer from other coͲmorbidities (e.g. mental
retardation, depression)which could have a greater negative impact onQoL than
epilepsyalone.TheimpactofsuchcoͲmorbiditycansubstantiallyimpairQoL,making
aш50%seizurereductiongain(ornot)moreorlessnegligible.
Despite this accumulating evidence, experts acknowledge thatneurologists tend to
focuson thecontrolof seizuresand lack further interest inpsychosocialaspectsof
epilepsy.66SuchpsychosocialaspectshaveastrongassociationwithQoL; therefore,
the bioͲpsychosocial model may be the missing link between clinical outcome
measuresandQALYs. InordertocalculateQALYssuitable foreconomicevaluations,
utilities based on generic QoL measures have to be elicited. Perhaps even more
importantly, effort should be put into finding (or developing) a valid and reliable
preferenceͲbasedgenericQoLinstrumenttouseinepilepsyresearch.Thereareother
preferenceͲbasedgenericQoL instrumentsunderdevelopmentwhicharepotentially




psychometric properties of the QoL instruments within the field of epilepsy do,
however,needtoberesearchedbeforeimplementation.
Despite ongoing debates in the literature, there appears to be a relatively strong




for costͲutilityanalysis. Inaccordancewith theNICEguidelines, theDutchBoardof
HealthInsurance(CVZ)alsomentionstheEQͲ5Dasthepreferredoutcomemeasure68,
the use of TTO as preferred utility elicitation method, values from the general
populationand(ifnecessary)theapplicationofmappingtechniques.
IfHTAresearcherswishclinicianstouseQALYs,anddecisionͲmakerstousetheresults




In an era of evidenceͲbased decisionͲmaking, the importance of using results from
scientific research in practice is not in doubt. The scientific community must,





conducted. While the other way around is possibly equally important, namely:
integratingpracticeͲbasedevidenceandcontextintotheresearchconducted.
Therefore, longͲterm costs and outcomes should be considered more often in
(economic)evaluationstudiestoprovideinsightintoallrelevantcostsandoutcomes
of interest to decisionͲmakers. Given that longͲterm trials, or performing an
intervention trial and a subsequent modelͲbased study to extrapolate the trial
findings, can be both timeͲconsuming and costly, one might wonder whether
decisionͲmakersshouldbelesscriticalaboutsoͲcalled‘lowqualitydata’.Mostofthe
scientificevidencebase is largely inadequate for clinicalpractice,as thesedataare
derived from regulatory trialswhich are too short for a chronic condition and use
outcomes of dubious relevance.69,70 These studies are doubleͲblind, randomized,




whether the difference between groups is due to the intervention rather than to
otherexternal influences (i.e.confounders).Tokeep thestudy freeofconfounders,















A recent example of a pragmatic study is the research conducted by Orosz and
colleagues.72Theirarticlepresents the resultsofa longͲterm (i.e.24months) study
evaluating the effects of the VNS in 347 patients. This studywas conducted as a
retrospectivemulticenterstudyandpresentedresponderratessimilar torates from






are available.One of the options is amultiͲcenter approach inwhich some of the
participatingcentersapplytheinterventionwhileothercentersdelivercareasusual.
In time,patientswhoare treatedwith the interventionarecomparedwithpatients
who are treatedwith care as usual.During the comparison, patients arematched
according tocertainvariables,suchassex,ageand theseverityof thedisease,and




theperspectiveofthepatient ishighly important.Makinguseofpatientregistries is
another option to collect realͲworld data prospectively. A patient registry is a
prospectiveobservationalstudyonsubjects,withcertainsharedcharacteristics (e.g.
epilepsy), that collects ongoing and supporting data over time on wellͲdefined
outcomes of interest for analysis and reporting.75Observational studies are ideally
designedforgatheringdataonthenaturalcauseofdiseasedevelopment. Inastudy
investigatingtheeffectoftakingobservationaldataintoaccountformetaͲanalyses,it
was found that including observational studies inmetaͲanalysesmay improve the
inferencebasedononly randomized trialsand furthermore, thatobservationaldata







use of data from registries instead of RCTs, external validitywould be traded for
internalvalidity.Patientregistriescanbecreatedformanypurposes:todescribethe
natural history of disease, to determine clinical effectiveness or costͲeffectiveness




In order to overcome such limitations, it is of utmost importance that a patient
registry isdesignedwith respect to itsmajorpurpose,with theunderstanding that
different levelsof rigormaybe required for registriesdesigned to address focused
analytical questions to support decisionͲmaking, in contrast to those intended
primarilyfordescriptivepurposes.Therearefivekeypointstoconsiderindesigninga
registryinordertoansweracertainresearchquestion:I)choosingastudydesign,II)
translatingquestionsof (clinical) interest intomeasurableexposuresandoutcomes,
III)choosingpatients for studyanddecideon theneed foracomparisongroup, IV)







andothercountries iscurrentlyhamperedbya lackof formalstructures tosupport
decisionͲmaking.76 To encourage more use of economic evaluation evidence and
thereby efficient allocation of public resources, clearer decisionͲmaking structures
needtobedeveloped.TheNationalInstituteforHealthandCareExcellence(NICE)in
London, is one of the first formal organizational structures for systematic and
transparent consideration of evidence in decisionͲmaking.77 Throughout the
development of the guidance, views of different stakeholders are considered,
includinghealthprofessionalsandpatientsandcaregivers.78
The NICE guideline, ‘The epilepsies’, takes the economic evidence of published
economicevaluationsonepilepsytreatmentsintoaccount.79Duringtheconstruction
of ‘The epilepsies’, health economists allocated an overall score to the existing











allrelevantalternativestrategies),or II)the interventioncosts lessthan£20,000per
QALYgainedcomparedwiththenextbeststrategy.79
In the Netherlands, the thorough epilepsy guidelines include a number of
recommendations about specific clinical problems. The guidelines are based,when
possible, on scientific research supplemented by the expertise of health care
professionalsandpatients.Theeconomicevidencehas,however,not(yet)beentaken
intoaccount.TheDutchguidelinesacknowledge the importanceof takingeconomic
evidence intoaccount.However,theyrefertothegaps inknowledgerelatingtothe
economicdataandquestionthequalityofthesmallnumberofeconomicevaluations.
The developers of the Dutch guidelines are not alone in this statement; theNICE
guidelinesonepilepsyhavecomeunderfirefromseveralexpertswhosaythatthey
donotreflectclinicalexperienceandfocustoomuchondrugcostͲeffectiveness.69
In order to increase the quality of economic evaluations, HTAͲresearchers should
complywithmethodologicalstandardsdescribedingoodpracticeguidelines34Ͳ37when
planning and designing new economic evaluation studies. The reporting of studies
could be improved by using quality assessment checklists, which identify
methodologicalaspects thatareessential ineconomicevaluation (e.g.36,80Ͳ82). LongͲ




of a Dutch clinical epilepsy guideline incorporating HTA aspects would be a step
forwardinbringingthetwoworldsclosertogether.Suchaguideline,however,should
not override the responsibility of health care professionals and others to make
decisionsappropriatetothecircumstancesofeachpatient.Thesedecisionsshouldbe
basedon shareddecisionͲmaking: in consultationwith,andwith theagreementof,





obtain greater insight into themeasurementofQoL in (intractable) epilepsy.More
researchisrequiredinordertoinvestigatethereasonsbehindourfailuretomeasure
improvementsinQALYswithgenericQoLinstrumentsinpatientswhowerelabeledas
responders in chapter 7.Obviously, for an economic evaluation to be a legitimate
policytool, itsessentialelementsneedtobemeasured inamethodologicallysound








preferences forhealthstatescanbe included inestimatesof thebenefitofmedical
interventions. Inchapter2,weapproachedthegeneralpublictoobtainpreferences
for epilepsy health states. Subsequently, it might be valuable to obtain patients’
preferencesregardingtheirownhealthstateandcomparethesewiththosefromthe
general public. Patient preferences towards QoL can be a relevant source of
information;how this shouldbedone,mightbe theaim for further research.Both
viewpoints (i.e. patient and general population) would seem reasonable and
compelling;thechallengeis,therefore,toinvestigatepossiblewaysofcombiningthe
differentsourcesofinformationintelligently.
A thirdrecommendation is tousedecisionͲanalyticalmodelling inorder tocompare
treatmentoptionsforrefractoryepilepsyandtoestimatelongͲtermcostͲutilitywhen
new data becomes available. A related recommendation concerns the value of




the costs of further research, it is potentially costͲeffective to acquire more
information83.Thevalueofeachofthe inputscanalsobeassessed,thusprioritizing
further research by identifying those inputs forwhichmore precise estimates are




other treatments in epilepsy as they seem to pose a large economic burden.
Prospective research is needed to estimate the exact burden, especially in newly
diagnosedpatientsorpatientsstartinga‘new’therapy,astheirsubjectivesideͲeffects
willbedirectly related to initiated therapy. Finally, it is recommended thatpatient
preferencesinepilepsy,relatedtodiagnostics,treatment,outcomesandsideͲeffects,
areinvestigated.Knowledgeabout(patient)preferenceswillbeinformativeforpolicyͲ
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are interested intherelativeeffectivenessandefficiencyofmedical interventionsto
support optimal priorityͲsetting. Health Technology Assessment (HTA) is a field of
researchthataimstoinformhealthpolicymakersinthesedecisionsbyexaminingthe
medical, economic, social and ethical implications of (medical) interventions. This
thesisreportsonHTAissuesbyfocusingonseveral(methodological)challengesinthe
fieldofepilepsyandevaluating thecostͲeffectivenessof theketogenicdietand the
vagusnervestimulatorforchildrenandadolescentswithintractableepilepsy.

Chapter 1 provides some background information on HTA research and epilepsy.
Epilepsy is a neurological disease characterized by epileptic seizures. Epilepsy is
usuallytreatedwithdailyantiepilepticdrugs(AEDs)and insomecasestheketogenic
diet (KD) or the nervus vagus stimulator (VNS)may be required. HTA is amultiͲ
disciplinaryfieldofpolicyanalysisthatstudiesnew interventions.Theobjective isto
provideabridgebetween theworldof researchand theworldofdecisionͲmaking.
Thischapter reports, furthermore,on thechallengesofHTA research in the fieldof
epilepsy,addressestheresearchquestionsandgivesanoverviewofthethesis.

Chapter 2 reports a study exploring the preference values (utilities) assigned to
epilepsyhealthstatesbythegeneralpublic.Itdemonstratedthatseizureseverityhad
a largernegative influenceonqualityof life (QoL) than seizure frequencyand sideͲ
effects.QoLisaveryimportantoutcomemeasure,notonlyforpatients,butalsoasan
inputforcostͲutilityanalyses.However,theessentialutilitiesarenotalwaysavailable.
This study delivers a practical utilityͲfunction for transforming clinically relevant
epilepsyoutcomemeasuresintoutilityestimates.

Chapter 3 describes a discrete choice experiment (DCE), which explores patient’s
preferences towards epilepsy diagnostics (e.g. EEG andMEG). Respondents were
asked tomake a series of binary choices between twomethods used in epilepsy
diagnostics,basedondifferentattributesand levels.Thestudyshowed thatMEG is
not necessarily more patientͲfriendly than a routine EEG in primary diagnostics.





Chapter 4 reports a study exploring the economicburden of commonAEDͲrelated
sideͲeffects. Although AEDs are, in most patients, very effective in reducing the
frequencyof seizures, they areoften accompaniedby (subjective) sideͲeffects. The
studyshowedthattheoverallsocietalcostsareestimatedtobe€20,751perpatient
peryear,ofwhichapproximately20%wasrelatedtohealthcarecosts.Theseresults
suggestthat it isan importantcostfactorwhichshouldbeconsidered intheoverall
assessmentoftheeconomicimpactofpharmacotherapy.

Chapter 5 presents a systematic review of existing economic evaluations of
interventions for the treatment of intractable epilepsy. It demonstrates that the
numberofeconomicevaluationsinthisfieldisrathersmallandthatthecomparison
between studies is hampered due to differences in study design and reported
outcome measures. Furthermore, methodological quality  of the studies shows
several weaknesses, including insufficient reporting of essential study details and




Ketogeen diet). A randomized controlled trial (RCT) is used to explore the costͲ
effectivenessoftheKDcomparedwithcareasusual(CAU)inchildrenandadolescents
withintractableepilepsy.AtrialͲbasedandmodelͲbasedeconomicevaluation,looking





months, the KD is a costͲeffective treatment optionwhen looking at the cost per
responder.However,nobenefitsintermsofQualityAdjustedLifeYears(QALYs)were










Chapter 9 discusses the overall findings of the research described in this thesis.
FurthermoreitaddressessomediscussionthemesrelatedtoHTAresearchinthefield
of epilepsy and provides recommendations for further research.More research is






outcomesand sideͲeffects,are investigated.Knowledgeabout (patient)preferences















































Health Technology Assessment (HTA) is een onderzoeksveld dat beleidsmakers
informeert in beslissingen door de medische, economische, sociale en ethische
implicatiesvan (medische) interventies teonderzoeken.Ditproefschrift rapporteert





Epilepsie is een neurologische ziekte gekenmerkt door epileptische aanvallen.
Epilepsie wordt gewoonlijk behandeld met dagelijkse antiepileptica (AEDs) en in












voor kostenutiliteit analyses. Echter, de essentiële utiliteiten zijn niet altijd
beschikbaar. Deze studie levert een praktische formule voor het omrekenen van
klinischerelevanteepilepsieuitkomstmatennaarutiliteiten.

Hoofdstuk 3 beschrijft een discreet keuzeͲexperiment,wat de patiënt voorkeuren
onderzoekt betreffende epilepsie diagnostiek (zoals EEG en MEG). Respondenten
werd gevraagd een reeks binaire keuzes te maken gebaseerd op verschillende
eigenschappenvandediagnostischetesten.DestudietoondeaandatMEGnietperse






Hoofdstuk 4  beschrijft een onderzoek naar de economische last van AEDͲ
gerelateerdebijwerkingen.OokalzijnAEDsveelalergeffectiefindebehandelingvan
epileptische aanvallen, gaan ze vaak gepaardmet (subjectieve) bijwerkingen. Deze
studie laatziendatdegemiddeldemaatschappelijkekosten€20,751perpatiëntper
jaar, waarvan ongeveer 20% gerelateerd was aan gezondheidszorg kosten. Deze
resultaten suggererendatdekostenvanbijwerkingeneenbelangrijkekostenpost is
diemeegenomen zoumoetenworden in de gehele schatting van de economische
impactvanfarmacotherapie.

Hoofdstuk 5 presenteert een systematische review van bestaande economische
evaluaties van interventies voordebehandeling van resistenteepilepsie.Het toont
aandathetaantaleconomischeopditgebiedvrijkleinisendatdevergelijkingtussen
studies wordt bemoeilijkt door verschillen in onderzoeksopzet en gebruikte
meetinstrumenten. Bovendien toont demethodologische kwaliteit van de studies
diverse zwakke punten,waaronder onvoldoende rapportage van belangrijke studie
detailseneenbeperktenalevingvandebestaanderichtlijnen.Dezetekortkomingen
in de bestaande literatuur belemmert een efficiënte en doelmatige toewijzing van
middelenbinnendeepilepsiegerelateerdegezondheidszorg.

Hoofdstuk 6 beschrijft de studie opzet van de zogenoemde KOEKͲstudie ( KOsten
Effectiviteit Ketogeen dieet). Een gerandomiseerde gecontroleerde studie opzet is
gebruiktomdekosteneffectiviteitvanhetKDtevergelijkenmetdegebruikelijkezorg
inkinderenenadolescentenmetresistenteepilepsie.EentrialͲbasedeneenmodelͲ





dat over een periode van 4maanden, het KD een kosteneffectieve behandeling is


















is nodig om de validiteit en betrouwbaarheid van andere potentiele voorkeursͲ
gebaseerdegeneriekekwaliteitvanleveninstrumententeonderzoeken.Verderishet












































































En dan, dan is het proefschrift af! Promoveren doe je niet alleen, daarom wil ik
iedereenbedankendiedirectofindirectaanmijnproefschriftheeftbijgedragen.
Om tebeginnenwil ikalle kinderen,oudersen vrijwilligersbedankendieaanonze









en andere projecten, ditwekte veel vertrouwen en ik heb dit als zeermotiverend






leiden.Daar heb ik bewondering voor. Jouw doeltreffende en kordatemanier van
werkenhebikalsheelprettigervaren,bedankthiervoor.
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studie en kon door je persoonlijke ervaringen en inhoudelijke achtergrond altijd
vanuitverschillendeperspectievenhetonderzoekbekijken.Hierdoorzorgdejijervoor
datallekantenvandezaakbelichtwerden,zonderdaarbijdedetailsuithetoog te
verliezen.Dewaardevollediscussiesover ‘hetmodel’ leverden steedsweernieuwe
inzichtenenideeënop,bedankthiervoor.
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afgelopen jaren, waarvoor ik hen bij deze allemaal hartelijk wil bedanken. Op de
eersteplaatsdeledenvanhetketogeendieetteamenallemensenwerkzaamopde
gedragswetenschappelijkedienstendeepilepsiepolivanKempenhaeghe.Zonderhen
was dit onderzoek nietmogelijk geweest. Dank aan alle specialisten, psychologen,





Danielle Lambrechts,we zaten inhet zelfde ‘promotieschuitje’. Jijalsneuroloogop
het klinischedeel, ik alsHTAͲeropheteconomischedeel,enook alwashet soms
moeilijk,we hebben het tochmaarmooi gedaan! Zonder jouw inzet en expertise









Dr.JannekeGrutters,bedanktdat ikbij jeterechtkonmetdemodelleringsstudie. Ik
heb de dagen op het Radboud als zeer leerzaam en ontzettend gezellig ervaren.
Zonder jouwashetnooitgelukten ikzalnooitvergetendat jezelfstijdens jeverlof
hetartikelvancommentaarhebtvoorzien!
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Sylvie en Zita bedankt voor de gezelligheid op de Boondert (en daarbuiten).We
moetensneldatreünieͲetentjegaanplannen,wantikbenergbenieuwdhoehetmet
jullieallemaalgaat!OpDub30wilikmetnameBrigitte,Suus,Joan,Mitchel,Bramen




En dan natuurlijk mijn lieve kamergenootjes van 0.044!Wat had en heb ik een
ontzettend fijne en gezellige tijd inMaastricht endat is echt aan jullie te danken!
LieveCindy,alshtaͲphdͲlotgenootjeswerdenwebijelkaaropeenkamergezetenhet
kliktemeteen.Vaak genoeg hebbenwe tranen gelachen!Heel veel succesmet de
afrondingvanjouwpromotietraject.LieveJanneke,inmiddelsmamavantweeknappe
kereltjes!Jijbentechthet luisterendoorvanonzekamerendatkwamvaakgenoeg
goedvanpas.Ook jijveel succesmetdeafrondingvan jouwpromotietraject.Lieve
Arianne,van jouwnuchtereenhumoristischekijkopdewereldkan ikgeengenoeg





deafgelopen jaren.Ook sta je,alsereen feestje, festivalofbruiloftgeregeldmoet





De “BudelͲ enNederweertgroep”, alfabetisch: Anne en Jos,Daphne,Guus en Kim,
ImkeenMitchell, Jantine, JelleenSabella, JordieenMaarten,LauraenMark,Loet,
Marcel,Martien enMirthe,Martijn enMieke,Nanneke enNiels,Niek enCharelle,
RensenMalou,SimoneenJoris,StefanenInge,Stephan,Tessa,WillemenSuus,Wim
enMariska,enWouter.Demeestevan jullieken ikalvanafdemiddelbare school.
Wathebbenwe samen veelmeegemaakt enwatben ik ontzettendblijmet jullie!
Jullie liggenaandebronvanvrijwelalleswat ikdoebuitenmijnwerk,endaarvoor





bedanken voor de interesse in mijn proefschrift de afgelopen jaren en voor de














Lieve papa enmama, bedankt voor alleswat jullieme hebbenmeegegeven in dit
leven. Zonder julliehad ikhiernooit gestaan!Bedankt voordemogelijkheidende
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proposal and worked partͲtime as a junior researcher at the epilepsy center
Kempenhaeghe.
From 2010 to 2014 Reinaworked on her PhD thesis focusing on HTA, preference
studies and economic evaluations in the field of epileptology. Aside from her PhD
research, Reina initiated and prepared (honored) research proposals, supervised
severalbachelor,masterandPhD students,andworked togetherwith several third
partiesonamodelͲbasedeconomicevaluationofmedicationforinvasiveaspergilosis.
Reina is the viceͲpresident of the International Society of Pharmacoeconomics and
OutcomeResearchStudentChapterMaastrichtUniversity.Furthermore,shefollowed
coursesondiscretechoiceexperimentsattheuniversityofGalway,Irelandandatthe
universityof Sydney,Australia andpresentedher researchon several international
andnational conferences. Shewas theDutchwinnerof PfizerHTAcademyprice in
2011and(coͲ)authoredupto15articles(8published,7submitted)for international
journalswithanimpactfactor.















































in theyear2010.About30%of thepatientswithepilepsy suffer fromuncontrolled
seizuresdespitetheuseofmanyantiepilepticdrugs(AEDs)(i.e.intractableepilepsy).
Epilepsymortalityratesarerelatedtoyoungpatientswithsevereintractableepilepsy
in combinationwith otherneurological problems and/ormental retardation. Living
withepilepsy canbeagreatburden for thepatienthimselfand thosearoundhim.
Patients with epilepsy heavily depend on informal care delivered by family and
friends.Sinceepilepticseizuresmostlyoccurunexpectedly, theymaycausephysical
harm, as well as psychological stress due to their unpredictability. Epilepsy can
sometimes result in significantdisability, socialexclusionand stigmatization.People
with epilepsy commonly encounter problems in the following areas: education;
employment; driving; personal development; psychiatric and psychological aspects
and social and personal relationships. Currently the scientific and clinical attention
paidtotheroleoftheketogenicdiet(KD)isnegligible.ThismeansthataKDisoften






















Table10.1 Target groups, related activities and products and an indication of innovation level and
realization.




























of new antiepileptic drugs.Most individualswith epilepsy can successfully control




sometimes difficult. Therefore, ourmasterͲchef developed tastymeals by using a
specialMCTͲpowder to turnMCT oil into tasteful cream, paste and mayonnaise.
Recipesarepresentedonourwebsite.
Implementation
At the moment we are building a new website to replace the former






and dietician can view their personal data.With this, the dietician and/or treating
physician can anticipate on experienced sideͲeffects or the level of ketosis by
changing the diet. The development of this new website is sponsored by fonds
NutsOhra,CZFonds,EpilepsiefondsandZonMw.

